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     Ovarian cancer is the deadliest of gynecologic cancers and is usually 
diagnosed at advanced stage due to invalidated screening test. Although 
carboplatin has been used for treating ovarian cancer for years, high-grade serous 
ovarian cancer expressing a constitutively active form of the intracellular domain 
of Notch 3 develops resistance to this platinum-containing drug. Thus, finding a 
novel treatment or therapeutic targets are necessary. Here we test the hypothesis 
that the combinational treatment of methylseleninic acid (MSeA) and carboplatin, 
two chemicals displaying overlapping effect on DNA damage response, may 
target Notch 3 for improved efficacy on ovarian cancer treatment. The 
OVCA429/NICD3 cells expressing an activated form of Notch 3 were resistant to 
carboplatin, but co-treatment with MSeA synergistically sensitized the cell to an 
extent similar of that in OVCA429/pCEG control cells. The synergistic effect can 
be suppressed by the presence of a hydrogen peroxide scavenger N-acetyl 
cysteine (NAC) and kinase inhibitors of ATM and DNA-PKcs. In summary, 
MSeA and carboplatin synergistically sensitize OVCA429/NICD3 cells in a 
pathway involves oxidative stress, ATM and DNA-PKcs, suggesting a new 
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CHAPTER 1: DNA DAMAGE RESPONSES, CARBOPLATIN, 
SELENIUM AND CANCER 
 
1.1 DNA CROSSLINKS 
     The unwinding and separation of the two strands of DNA are crucial for DNA 
replication and transcription (Deans and West, 2011). DNA crosslinks prohibit 
DNA double helix from separation by forming covalent bonds in bases in the 
same strand (called as intrastrand crosslinks), between opposite strands (known as 
interstrand crosslinks), or between protein and DNA (named as DNA-protein 
crosslinks). They may be induced by endogenous sources, such as the by-products 
of lipid peroxidation - acrolein, crotonaldehyde (Kozekov et al., 2003), β-
unsaturated aldehydes (Stone et al., 2008), and exogenous sources, including 
aldehydes, heavy metal ions, ionizing radiation, UV light, and chemotherapeutic 
agents (Ide et al., 2010). In mammalian cells, it is estimated that 80 events of 
interstrand crosslinks occur naturally in one cell per day (Bernstein and Bernstein, 
1991). Comparing the incidence of interstrand crosslinks to the incidence of other 
DNA damages, this number is quite small but they are refractory to be repaired.  
     The formation of different types of DNA crosslinks, which result in contortion 
of structure (Rabik and Dolan, 2007), depends on factors such as types of 
inducers, cellular metabolism, cell cycle phase, and environmental toxicants. 
Based on the clastogens, DNA lesions have various chemical structures, physical 
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conformations, and biological consequences (Barker et al., 2005). Mixed 
population of the lesions is formed by DNA crosslinking agents (Gruenert et al., 
1985). Interstrand crosslinks have usually smallest percentage of lesions but are 
the most toxic ones.  
     DNA damage response pathways can alert cells to initiate an appropriate 
response to clastogens through DNA repair checkpoint and signal transduction. 
The adduct causes DNA distortion which is recognized by cellular proteins that 
involved in DNA repair pathways. Based on the types of damage structure, DNA 
adducts can be recovered by four major DNA repair pathways: (1) nucleotide-
excision repair (NER), (2) base-excision repair (BER), (3) mismatch repair 
(MMR), and (4) double-strand-break repair (DSB). NER, BER, and MMR are the 
three possible excision-repair pathways to fix DNA crosslinks. These three DNA 
repair pathways repair DNA damage through excising damage sites, followed by 
resynthesizing using the opposite strand as a template.  
     If the lesions are unable to be repaired, they cauese permanent genome 
instability or cell death (Kelland, 2007; Barker et al., 2005; Muniandy et al., 
2010). To control cell growth, differentiation, and stress responses, signal 
transduction pathways are activated by sensor proteins including ataxia 
telangiectasia-mutated (ATM), checkpoint kinase 1 (CHK1), checkpoint kinase 2 
(CHK2), p53, p21, and the breast cancer associated 1 (BRCA1) (Kelland, 2007). 
However, DNA crosslinks-induced cell death induction by platinum-based 
chemotherapeutic reagents is not completely understood. Interstrand crosslinks 
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can block the processing of the DNA replication fork by inhibiting the separation 
of double helix. If the cleavage of a DNA replication fork occurs, it can lead to 
DNA double strand breaks. Distorted structure also prevents binding of DNA-
interacting proteins to DNA. Interstrand crosslinks may induce p53-dependent 
apoptosis or p53-independent mitotic catastrophe (a cell is destroyed during 
mitosis when apoptosis is not working) in tumor cells (Deans and West, 2011).  
 
1.1.1 Nucleotide excision repair (NER) 
     NER is the major pathway to remove distorted, bulky lesions. Bulky lesions 
and helix-distorting DNA adducts are usually induced by UV light or bulky DNA 
adducts. Mutations in the genes controlling NER result in xeroderma 
pigmentosum (XP), Cockayne’s syndrome (CS), and trichothiodystrophy (TTD) 
(Costa et al., 2003). Patients with XP have mutations in one of the seven XP 
genes (XPA to XPG), while patients with CS carry mutations in one of the two CS 
genes (CSA and CSB). All of these genetic diseases with defective NER display 
photosensitivity and predisposition to sunlight-induced skin cancer (Cleaver et al., 
1994).  
     There are two sub-pathways of NER, transcription-coupled NER (TCR) and 
global genomic NER (GGR), which differ in the first few steps of DNA repair. In 
TCR, CS proteins (CSA and CSB) sense the bulky lesions and transduce signals 
to downstream mediators. On the other hand, in GGR, XPC/HR23B complex is 
the recognition protein that reaches the impair sites and causes DNA distortion. 
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Next, CS proteins and a domain on XPC interact with TFIIH and XPG for TCR 
and GGR, respectively, followed by recruitment of XPA or heterotrimeric 
replication protein A (RPA). Later, CS or XPC/HR23B damage-recognition 
proteins dissociate from damaged regions,  and then XPA and RPA facilitate the 
loading of XPD and XPB (Costa et al., 2003; Hoeijmakers, 2001). TFIIH is 
needed for transcription initiation while helicase XPB and XPD unwind and make 
a bubble structure of DNA near the unrepaired lesions (Evans et al., 1997). The 
unwound 24 to 32 bp bubble structure are removed by dual incision by the 
endonucleases XPG, excision repair cross-complementing-1 (ERCC1), and XPF. 
Finally, DNA synthesis and nick annealing are complete by DNA polymerase ε/δ 
and DNA ligase, respectively (Costa et al., 2003).  
 
1.1.2 Base excision repair (BER) 
     BER can correct non-helix-distorting base lesions after exposure to oxidative 
radicals, alkylating agents, ionizing radiation, or spontaneous base loss 
(Hoeijmakers, 2001). These clastogens can lead to single strand breaks (SSBs), 
small base damage, abasic sites, and 8-hydroxyguanine. The incidence of the 




 lesions per cell per day. 
However, there is no known genetic disorder associated with BER genes 
mutations possibly due to the essentiality to repair DNA through BER. 
    BER is categorized into two sub-pathways, short-patch (one nucleotide) and 
long-patch BER (more than one nucleotide), depending on the number of 
5 
 
impaired nucleotides, the cell cycle stage, and cell preference (Wei and Englander, 
2008). However, the exact mechanistic details as to how the cell decides which 
branch of BER to go through is not completely clear (Hoeijmakers, 2001). Short-
patch BER is the major pathway which can only repair one base at one time while 
long-patch BER can deal 2 to 10 nucleotides (Fortini and Dogliotti, 2006). They 
partially share the repair steps, such as damaged base removal, cleavage, and 
DNA resynthesis. DNA glycosylase is the first enzyme responsible for cutting the 
N-glycosylic bond that links DNA bases to sugar molecules. There are three 
glycosylasese, including uracil-DNA glycosylase (UNG), thymine-DNA 
glycosylase (TDG), and 8-oxoguanine glycosylase (OGG1) (Darwanto et al., 
2009). Glycosidase cleavage generates an intermediate apyrimidinic/apurinic (AP) 
or abasic site, followed by AP endonuclease 1 (APE1) cleavage of the 
phosphodiester backcone to expose a 3-OH and a 5’-deoxyribose-5-phosphate 
(5’-dRp) (Demple et al., 1991; Gellon et al., 2008). Next, APE1 interacts with 
DNA polymerase β (Pol β) that exhibitsa AP lyase activity so they can cut off the 
5’-dRp residue and synthesize the right nucleotides. The nick is then filled by the 
XRCC1/DNA Ligase III complex. 
      Long-patch BER also needs DNA glycosylase, APE1, and DNA Pol β, but 
they can repair longer impaired nucleotides than short-patch BER does. However, 
for long-patch BER, DNA Pol β interacts with the proliferating cell nuclear 
antigen (PCNA) and the replication factor C (RFC), displacing a strand of DNA 
near the unrepaired lesions and also generating a flap of 2 to 10 nucleotides 
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(Matsumoto, 2001). The flap is cleaved by flap endonuclease 1 (FEN1), followed 
by gap filling through DNA ligase I.  
 
1.1.3 Mismatch repair (MMR) 
     Mismatch repair corrects DNA mismatches that escape proofreading during 
DNA replication (Kunkel and Erie, 2005). Insertion/deletion lesions (IDLs) due to 
template slippage is also recognized and repaired by MMR (Hoeijmakers, 2001). 
DNA mismatch is first recognized by the MSH2/MSH6 (MutSα) and the 
MSH2/MSH3 (MutSβ) heterodimers with their respective substrate preferences. 
MutSα prefers to recognize base-base and small insertion/deletion mismatches 
while other IDLs are bound by the MutSβ (Jiricny, 2006). Next, MutSα and 
MutSβ consume one ATP to substitute mismatched bases or IDLs and pull out 
DNA damage. MutS then forms a complex with MutL that has three forms 
(MutLα, MutLβ, and MutLγ). MLH1, a subunit of MutLα, contains two 
interaction domains: one for MutS and another for PMS2, PMS1, or MLH3. 
When MLH1 interacts with PMS2 to form MutLα, MutLα functions as a 
matchmaker or facilitator; they mediate events in MMR. The MLH1-associated 
complex is responsible for the recruitment of proteins needed for excision and 
repair synthesis. A number of DNA metabolism proteins including PCNA, RPA, 
RFC, exonuclease I, DNA Pol ε/δ, and endonuclease FEN1 coordinate and excise 
DNA mismatches, resynthesize correct nucleotides, and ligase the nick (Kunkel 
and Erie, 2005). Different from BER and NER, MMR can discriminate newly 
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synthesized DNA strand from the parental strand according to the interaction 
between MutLα and PCNA (Clark et al., 2000). 
     Loss of expression in MMR enzymes, such as hMLH1 and hPMS2, causes 
DNA replication error and insertion/deletion, leading to spontaneous mutations. 
Particularly, when the errors occur in short repeated nucleotides sequences, it is 
known as microsatellite instability (Misdraji et al., 2004). Mutations in hMLH1 
gene have been shown to be associated with increased risk of developing 
colorectal cancer. Based on many epidemiologic studies, it has been found that a 
large proportion of people with hereditary non-polyposis colorectal carcinoma 
history (HNPCC) have a tendency in MMR genes mutations, over 90 percent of 
which occur in hMLH1 and hMSH2 (Mitchell et al., 2002). 
  
1.1.4 Double-strand-break repair 
     Unrepaired DSB may induce apoptosis and permanent cell cycle arrest. 
Mammalian cells have two major pathways to repair DSB: homologous 
recombination (HR) and non-homologous end joining (NHEJ). NHEJ is thought 
to contribute substantially to DSB repair throughout the cell cycle whereas HR is 
only involved in late S and G2 phases (Rothkamm et al., 2003). Both NHEJ and 
HR are involved in replication fork-induced DSB and one-ended DSB. However, 
two-ended DSB is usually reconnected by HR (Lundin et al., 2002). 
     As a result of DSBs, not all damage termini are complete nucleotides, instead, 
many are non-conventional end groups. Impaired DNA ends may contain 
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abnormal 3’ phosphate groups, 5’ hydroxyl groups, damaged backbone sugar 
residues, and damaged DNA bases. These groups need to be deleted or modified 
so that they can meet the requirements of DNA ligation – 5’-phosphate and 3’-OH 
group (Chappell et al., 2002).  
     In the process of NHEJ, Ku70 and Ku80 form a heterodimer that binds 
strongly to the ends of the DSB in order to stabilize the damage. The dimer then 
interacts and forms a complex with DNA-PKcs (the catalytic subunit of DNA-PK). 
DNA- PKcs is autophosphorylated in order to trigger the kinase activity of DNA-
PK complex, which facilitates the recruitment of other repair proteins to the DSB 
site. If DNA hairpin is formed as intermediates in V(D)J recombination (a genetic 
recombination in the early stages of immunoglobulin and T cell receptors 
production) (Sadofsky, 2001), DNA-PK complex recruits the structure-specific 
Artemis nuclease to DNA ends (Ma et al., 2005). Artemis/DNA-PK complex then 
functions as an endonuclease for cleaving 3’-ssDNA overhangs after polymerase 
has the new strand (Budman and Chu, 2005). Once the work is done, the 
Artemis/DNA-PK complex may fall apart from Ku-DNA complex to allow 
following repair steps (Lieber et al., 2004). Finally, the XRCC4/DNA ligase IV 
complex and XRCC4-like factor (XLF) are localized by DNA-PK complex to 
DNA ends to join two strands of DNA for ligation (O’Driscoll and Jeggo, 2006; 
Lord et al., 2006). When encountering damaged DNA ends with 3’ phosphate 
groups or 5’ hydroxyl groups, polynucleotide kinase (PNK), which functions to 
phosphorylate 5’-OH groups and removes 3’-phosphate ends, is thought to play 
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an important role in the modification of damaged DNA termini in human cells. 
XRCC4 interacts with PNK to permit the conversion of DNA ends (Koch et al., 
2004). However, if NHEJ is inhibited by inactivation of either XRCC4 or DNA-
PKcs, PNK is unable to convert damaged DNA termini (Chappell et al., 2002). 
This indicates the integral partnership between the above three proteins.  
     NHEJ is generally considered as a homology-independent DSB repair pathway 
that directly joins two DNA ends. Therefore, although NHEJ efficiently rejoins 
the DSB ends, nucleotides may lost at the sites of damage (McHugh et al., 2000) 
that lead to mutagenic changes (Lord et al., 2006).  
    On the contrary, HR rejoins DSB ends using a DNA sequence homologous in 
the genome (sister chromatids, homologous chromosomes, or repeated regions on 
the same or opposite chromosomes) as a template so the repair is considered 
accurate and known as an error-free repair mechanism (Shrivastav et al., 2007). 
The initial step of HR is to generate single-stranded DNA (ssDNA) in order to 
allow numerous factors for resynthesizing DNA. The coordination of the C-
terminal binding protein interacting protein (CtIP), exonuclease-1, and the 
MRE11-RAD50-NBS1 (MRN) complex is required for DNA resection. In 
particular, MRE11 exhibits ssDNA endonuclease and 3’ to 5’ double strand DNA 
(dsDNA) exonuclease activities for the formation of a 3’ ssDNA overhang (Lewis 
et al., 2004; Langerak and Russell, 2011; Limbo et al., 2007). A 3’-overhang is 
protected by RPA so that secondary structures cannot be formed. RAD51 is then 
localized to displace RPA by the breast cancer associated protein 2 (BRCA2). 
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Binding of BRCA2 to ssDNA results in the formation of a DNA-protein filament 
that facilitates the search for homologous templates, the invading for the target 
homologous sequence, the initiation of the DNA synthesis, and the formation of 
the crossover X-shape Holliday junction (Hinz, 2010). Next, dNA polymerases 
can extend the 3' end of damaged strand while RecQ helicases can unwind the 
undamaged DNA duplex. After sufficient DNA synthesis, the Holliday junction is 
resolved by cleavage. The final repair processes require the removal of flaps, 
filling in the gaps, and ligating the remaining nicks to complete the repair of DSB 
by HR (Helleday et al., 2007). Because HR rejoins DSB by using sister chromatid 
as a template, it allows the cells to repair DNA with high fidelity.  
 
1.1.5 Double strand break induced signal transduction pathways 
     DNA double helix is supposed to be unwound by helicases before DNA 
polymerase starts replicating it. However, DNA crosslinks prevent DSB from 
unwinding. Therefore, during S phase, when processing mediators encounter 
crosslinks at the site of replication fork the replication fork may collapse and DSB 
are formed as intermediates in an attempt to restart replication (McHugh et al., 
2000; McCabe et al., 2009). The DSBs can either be repaired by HR or NHEJ, or 
induce ATM-dependent cell cycle arrest (Lord et al., 2012). To date, by 
proteomics analysis, the ATM kinase is known to phosphorylate more than 700 
substrates (Matsuoka et al., 2007). ATM is the heart of DSB repair pathway and 
can also be activated by oxidative stress. The kinase activity of ATM can be 
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induced throughout the cell cycle (Cortez, 2005). It is involved in the maintenance 
of genome stability and in the activation of DNA damage checkpoints (O’Driscoll 
and Jeggo, 2006). People with mutations in the ATM gene are characterized by 
cerebellar ataxia, telangiectasia, immunodeficiency, and a high incidence of 
malignancy. Cells derived from AT patients show hypersensitivity to ionizing 
radiation, genome instability, and cell cycle checkpoint deficit (Iijima et al., 2008). 
     MRN complex is thought to be the first sensor protein that rapidly recognizes 
and binds to the DSB damage sites. Two units each of Mre11 and Rad50, and one 
Nbs1 assemble the U-shape flexible MRN complex. When MRN complex binds 
to the 2-ended DSB site, the Mre11 dimer synapses symmetrically the two ends of 
DNA. On the contrary, when binding the 1-ended DSB substrate, the Mre11 
dimer binds to one single DNA strand and shapes an asymmetric structure. The C 
terminus of Nbs1 localizes MRN complex to the nucleus (Williams et al., 2010) 
and recruits ATM to the damaged DNA. Mutations in Nbs1 can result in 
Nijmegen breakage syndrome, a rare autosomal recessive disorder exhibiting 
chromosomal instability. In addition, autophosphorylation of ATM on Ser1981 is 
required for activation of its kinase activity and the dissociation of the kinase-
inactive ATM dimers to form the active ATM monomer. MRN complex not only 
induces but also contributes to ATM kinase activation by increasing the affinity 
between ATM and its substrates through protein-protein interactions (Lee and 
Paull, 2005).  
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     Another early step in the response to DSB is the phosphorylation of H2AX 
histone protein at Ser-139 by ATM or the DNA-PK complex, generating γH2AX. 
After DSB occurs, γH2AX is phosphorylated within 1 to 3 minutes and marks the 
damage sites by forming microscopic foci in nucleoli (Lobrich, et al., 2010). 
γH2AX foci superficially attract DSB repair proteins to the surrounding DNA 
damage site. γH2AX expression levels shows a linearly correlation with the 
severity of DNA damage (Paull et al., 2000) and is known as an indicator of DNA 
breaks. The major function of γH2AX is to help retain activated mediators 
downstream ATM to the damaged site, including mediators of DNA damage 
checkpoint 1 (MDC1), tumor protein 53 binding protein 1 (53BP1), BRCA1, and 
structural maintenance of chromosomes 1 (SMC1) (Podhorecka et al., 2011). 
H2AX knockout in mice or knockdown in cells exhibited a significant increase in 
chromosome aberrations (Celeste et al., 2003).  
     Phosphorylation of CHK2, CHK1, and p53 by ATM occurs at sites of DSB 
throughout the nucleoplasm in the S phase of the cell cycle (Lord et al., 2012). All 
these proteins are involved in cell growth control. CHK1 and CHK2 are protein 
kinases that serve to amplify the DNA damage signal of ATM. After ATM-
mediated phosphorylation of CHK1 at Ser-345 and Ser-317, CHK2 at Thr-68, 
they can phosphorylate their major substrate, cell division cycle-25A (CDC25A) 
phosphatase, which is considered as an oncogene that promotes progression 
through S phase (Zou et al., 2001). CDC25A is a target of the E2F family that 
regulates S phase quiescence and is known to be overexpressed in several tumor 
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tissues, including breast and head and neck cancer. CDC25A overexpression also 
indicates a common consequence of being insufficient in suppressing a p53 
induced growth arrest (Ruppenthal et al., 2007). In normal cellular progressing, 
CDC25A activates the cyclin-dependent kinase 2 (CDK2) needed for DNA 
synthesis, but its expression is decreased in the response to DNA damage or 
stalled replication (Falck et al., 2001). However, the function of CDC25A is 
inhibited after extensive phosphorulation at multiple N-terminal sites by CHK1 
and CHK2, resulting in cell progression delay in the S phase and apoptotic 
responses (Uto et al., 2004; Li and Stern, 2005). 
     The tumor suppressor p53 is the negative regulation of cell progression. When 
it is directly activated by ATM or CHK2, p53 promotes the transcription of many 
downstream mediators that either stop cell cycle or induce apoptosis. A number of 
studies have found that p53 transcription is activated during early S phase and in 
cells progressing into S phase (Mosner et al., 1995; Reich and Levine, 1984). 
Interestingly, p53 also plays an important role in the S phase checkpoint. An 
examination in Swiss3T3 cells treated with the DNA damaging agent 
camptothecin showed that p53 protein levels increased earlier in S phase than in 
the progressing into S-phase. p21 is a gatekeeper protein whose expression is 
activated by p53,. In S phase of the cell with unrepaired DNA damage, p53 
induces the activation of p21 that binds to the complex composed of replication 
factor C, DNA polymerase d, FEN1 and, proliferating cell nuclear antigen, 
causing the disconnection from replication fork and the blockage of DNA 
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synthesis phase (Christmann et al., 20105). p21 activation also inhibits cyclin-
dependent kinase (CDK) function that causes cell cycle arrest. Consequently, the 
above actions of p53 prevent accumulation of irreversible genetic damage and 
maintain genome integrity, which may lead to permanent cellular transformation 
and carcinogenesis, (Janus et al., 1999; Takahashi et al., 2011). Thus, p53 has 
been considered as the “guardian of the genome”. 
 
1.1.6 The link between DNA crosslinks and cancer 
     Cancer cells generally proliferate faster and have less error-correcting 
mechanisms than healthy cells. Some chemotherapeutic drugs, such as carboplatin, 
kill cancer cells by inducing DNA crosslinks. However, DNA crosslink is also 
related to carcinogenesis in normal cells. Several lines of evidence indicate the 
link between carcinogenesis and DNA crosslinks. DNA crosslinking agents, such 
as formaldehyde and hexavalent chromium compounds that induce DNA-protein 
crosslinks, have been found to induce an increase in the population of p53 
mutation in people who are exposed to above chemical environments (Shaham et 
al., 2003; Hanaoka et al., 1997). These results may explain why some positions of 
physicians, laboratory assistants and technicians, hospital orderlies, and 
hexavalent chromium workers have high risk of cancer. Also, the positive 
association between DNA-protein crosslinks and p53 mutations indicates that the 
number of crosslink is a risk factor (Merk and Speit, 1998). In animal studies, pre-
cancer phenotypes, inflammation, hyperplasia, ulceration, and cellular atypia, 
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were observed in hairless mice that were treated with photoactivatable 
bifunctional psoralens and exposure to UV light in order to induce crosslinks 
(Dunnick et al., 1987). Both clinical and animal studies show a strong connection 
between crosslinks and cancer-related markers. 
 
1.2 NOTCH PATHWAY 
     Notch is an evolutionarily conserved membrane protein found from drosophila 
to vertebrates (Artavanis-Tsakonas et al., 1995). Notch is thought to function 
primarily as a transcriptional activator that plays important roles in controlling 
cell fate regulation, cell proliferation, and cell death during development and in 
various organs (Shih and Davidson, 2009). The Notch pathway covers a short-
range signaling mechanism between neighboring cells but results in gene 
expression changes (Kovall, 2008). The Notch pathway is an uncommon 
signaling pathway, whose activation does not need secondary messengers for 
amplification (Tien et al., 2009). The three main molecular constitutions in the 
Notch pathway are DSL ligands (Delta and Serrate in Drosophila, Lag2 in C. 
elegans), Notch receptors and nuclear effectors. To date, four Notch receptors 
have been identified. The N-terminal EGF-repeat region of the Notch 
extracellular domain (ECD) interacts with DSL ligand that changes the 
conformation of Notch receptor protein, triggering a series of proteolytic 
cleavages by tumor necrosis factor-α-converting enzyme (TACE), 
metalloprotease, and γ-secretase (Wang et al., 2008). TACE makes the first 
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cleavage, separating ECD from Notch protein. ECD then is trans-endocytosed 
into neighboring cells. The second cleavage is mediated by γ-secretase, releasing 
the Notch intraceullular domain (NICD) into cytoplasm. Subsequently, NICD 
translocates into the nucleus and interacts with nuclear effectors, the DNA-
binding CSL (CBF1, Su(H) and LAG-1) protein. The co-activator Mastermind 
(Mam) and other transcription factors are recruited to the CSL complex, 
repressing or activating target genes (Bray, 2006). The Notch pathway is 
complicated, which resolves equivalent cells into distinct fates due to small or 
weak differences of signaling amplification (Bray, 2006). However, the exact 
mechanistic detail as to how the cell decides what signals to amplify is not 
completely understood. 
1.2.1 Notch in cancer development and progression 
     Dysfunctional Notch guides cells towards malignant transformation. Many 
observations indicated the link between alternations in the Notch pathway and 
cancers. Interestingly, Notch can be oncogenic or anti-proliferative in cancer 
formation, depending on the type of signals (Lobry et al., 2011; Maillard and Pear, 
2003). Some studies have shown an anti-proliferative function of Notch in skin 
cancer, human hepatocellular carcinoma, medullary thyroid, cervical cancer, and 
small cell lung cancer. For example, p21 expression and the resultant G1/S arrest 
is upregulated by Notch 1 (Panelos and Massi, 2009). Furthermore, Notch 1 
induces caspase-3 activity, resulting in a decrease in proliferation (Okuyama et al., 
2004). Several studies reported that deletion of Notch 1 results in spontaneous 
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epidermal and corneal hyperplasia in old mice. Thick growing skins are sensitive 
to chemical-induced skin carcinogenesis that is regulated through β-catenin-
mediated signaling (Nicolas et al., 2003; Demehri et al., 2009).  
     On the contrary, data suggest that Notch signaling is pivotal in oncogenic 
functions due to the cross talk with oncogenic signaling pathways. In solid tumors, 
the Notch pathway promotes the transcription of  Hairy enhance of split family 
(Hes), nuclear factor-kappa B (NF-κB), vascular growth factor receptor (VEGF), 
mammalian target of rapamycin (mTOR), p21, p27, protein kinase B (Akt), 
estrogen receptor (ER), androgen receptor (AR), and epidermal growth factor 
receptor (EGFR) (Rizzo et al., 2008; Wang et al., 2008; Wang et al., 2010). All 
these NICD-targeting genes are involved in tumor development and progression. 
However, in the haematopoietic system, Notch also could be either oncogenic, 
such as T-cell acute lymphoblastic leukaemia, a disease characterized by Notch 1-
activating mutations (Aifantis et al., 2008), or suppressive in chronic 
myelomonocytic leukaemia by downregulating the Hes1 expression (Klinakis et 
al., 2011). Constitutively active Notch 3 expression induces tumorigenesis by the 
sustained expression of pre-T cell receptor (TCR) and the continuing expression 
of NF-κB in T-cell leukemogenesis (Bellavia et al., 2000). Moreover, high Notch 
3 protein expression is observed in ovarian serous carcinoma, indicating a role of 
this protein in tumorigenesis. Furthermore, inactivation of Notch 3 leads to 
suppression of cell proliferation and induction of apoptosis (Park et al., 2006). 
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Therefore, depending on the cell types and Notch-targeted genes, the Notch 
pathway can be considered as either a tumor suppressor or a tumor promoter.  
 
1.3 CARBOPLATIN 
     It all starts by the accidental discovery of the chemotherapeutic potential of 
cis-diamminedichloroplatinum(II), or cisplatin, by Barnett Rosenberg at Michigan 
State University , East Lansing, United States (Kelland, 2007). When the 
Rosenberg Lab was analyzing chemicals in order to understand whether electric 
and magnetic dipole fields are involved in cell division regulating, they found the 
neutral cis-isomer [PtII (NH3)2Cl2], which turned into cisplatin later. This finding 
was published in 1965 (Rosenberg et al., 1965) and the following test was done 
by 1969, showing the anticancer effect in mice (Rosenberg et al., 1969). Based on 
its chemotherapeutic effect, cisplatin was approved by the US Food and Drug 
Administration (FDA) in 1979 to be a clinical anticancer drug. However, cisplatin 
continued to show severe side effects and high toxicity. If the leaving group of 
platinum-based drug is more stable than chloride, the toxicity of cisplatin 
becomes lower (Kelland, 2007). Based on the theory, many platinum-based drugs 
have been designed in an attempt to reduce the side effects of cisplatin. Thus, the 
most promising second generation platinum analog carboplatin was developed.  
     The worldwide approved carboplatin has been used clinically since it was 
introduced in mid-1980s by the collaboration between Johnson Matthey Plc (JM) 
and the Institute of Cancer Research (ICR) in London (Kelland, 2007). 
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Carboplatin shares the same mechanism of action with cisplatin but has decresaed 
toxicity (Cruet-Hennequart et al., 2009) due to a slow leaving group, a bidentate 
dicarboxylate (CBDCA) ligand. Besides, carboplatin has a low protein binding 
affinity so it has longer half-life of ultrafilterable platinum and a higher 
cumulative urinary platinum excretion in comparison to cisplatin (van der Vijgh, 
1991). Therefore, carboplatin dosage can be given up to 4-fold higher than 
cisplatin. Although carboplatin functions on lung, colorectal, head and neck 
cancers, as well as lymphoma and melanoma, it is preferentially used to treat 
ovarian and testicular cancer (Wheate et al., 2010).  
 
Figure 1.1 Carboplatin Structure. Carboplatin is a second generation platinum-
based chemotherapeutic drug. Carboplatin contains a slow leaving group - 
bidentate dicarboxylate (CBDCA) ligand instead of the two chloride ligands 
appeared in cisplatin. This makes it less toxic compared to cisplatin. 
 
1.3.1 Mechanism of action of carboplatin 
     It is crucial to understand the mechanism of action of a drug in order to set a 
reference for durg design and modification. Based a drug’s biochemical and 
physiological impact, effective analogous compounds with less toxicity and side-
effects can be synthesized. For the design of anticancer drugs, knowing how the 
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chemical acts is usually the first step, followed by steps tomodify drugs with 
different functional groups and to find the best working environments.  
     Carboplatin [cis-Diammine (1,1-cyclobutanedicarboxylato) platinum(II)] 
belongs to the large group of chemotherapy drugs with DNA alkylation function 
(Kojima et al., 1994). During transporting and targeting, carboplatin becomes 
aquated, losing oxalate ions [C2O4
2-
] and gaining two water molecules. This 
negatively electrophile carboplatin can interact with nucleophilic molecules such 
as DNA strands. When attacking DNA, carboplatin primarily binds to the N7 
atom of the imidazole ring of guanosine (G) and to a lesser extent to adenosine 
(A), generating three different forms of DNA lesions, including monoadducts, 
intrastrand crosslinks and interstrand crosslinks (Cruet-Hennequart et al., 2009). 
Monoadducts are first formed while one water molecule is removed from 
carboplatin (Rabik and Dolan, 2006). However, greater than 95% of monoadducts 
will then transform into crosslinks and left only around 2% monoadducts (Table 
1.1) (Deans and West, 2011). Intrastrand crosslinks, which involve adjacent bases 
to one another on the same DNA strand such as GpG 1,2 intrastrand (60 to 65%) 
and ApG 1,2 intrastrand (20 to 25%), comprise the majority of all adducts. 
Additional minor product of intrastrand crosslinks include GpXpG 1,3 intrastrand 
crosslink that sandwiches a base between the two platinated guanosine 
(approximately 2%) (Rabik and Dolan, 2006; Kelland, 2007; Unger et al., 2009). 
In addition, less than 5% of interstrand crosslinks contain two guanosines from 
the opposite DNA strands (McHugh et al., 2001).  
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~2% GpG 1,2 intrastrand 
crosslinks: 60-65% 
ApG 1,2 intrastrand 
crosslinks: 20-25% 
GpXpG 1,3 intrastrand 
crosslinks: ~2%  
G-G interstrand 
crosslinks: <5% 
Table 1.1 Percent of three types of carboplatin-induced DNA adducts.  
 
     All crosslinks result in DNA strand conformation change such as unwinding or 
bending toward the grooves. There are different theories underlying the link 
between cytotoxicity and DNA lesions on the basis of the level of distortion in the 
DNA strand. Some believe that interstrand crosslinks that can unwind DNA up to 
80
o
 are more toxic than other DNA lesions because DNA strand separation is 
inhibited (Deans and West, 2011). On the other hand, some concern that 1,2 
intrastrand crosslinks have high cytotoxicity since the ineffective trans isomer of 
carboplatin is only able to form 1,3 intra- and interstrand crosslinks , owing to 
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stereochemical constraints (Eastman and Barry, 1987). In conclusion, carboplatin 
is used as an anticancer drug to kill tumor based on the property to induce the 
formation of DNA crosslinks.  
 
1.3.2 Adverse effects of Carboplatin 
     The cytotoxicity for killing cancer results from carboplatin-induced DNA 
adducts. DNA lesions may lead to DNA replication inhibition, cell cycle arrest, or 
even apoptosis (Unger et al., 2009). However, though insufficient dose may result 
in resistance later on, toxicity restricts the dosage for cancer treatment. Cisplatin 
causes very serious nephrotoxicity and peripheral neuropathy (Donzelli et al., 
2004). Nephrotoxicity is primarily due to the platinating agent uptake by proximal 
tubule cells of the nephron (Yao et al., 2007). Proximal tubular epithelial cells are 
found to show 5 time higher concentration of cisplatin than in serum level (Arany 
and Safirstein, 2003). Nephrotoxicity can be controlled by giving diuretics and 
pre-hydration while there is no way to deal with peripheral neuropathy. By 
contrast, carboplatin does not show severe side effects on kidney and peripheral 
neurons but causing myelosuppression (Wahstaff et al., 1989). Myelosuppression 
which is the chief reason of dose limitation is a decrease in blood cells production, 
leading to severe thrombocytopenia (a platelet count below 50,000 per μL) and 
less often leucopenia (the total white cell count drops below 4000 per mm
3
). 
Gastrointestinal toxicity also occurs in most patients receiving carboplatin, but 
nausea and vomiting symptoms are usually delayed for a few hours later or are 
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mild to moderate than patients receiving cisplatin. When conventional carboplatin 
dose is given, 20 to 40% of patients have thrombocytopenia and less than 20% get 
leucopenia (Rabik and Dolan, 2006). In addition, high dose carboplatin can result 
in life-threatening toxicity.  
 
1.3.3 Carboplatin resistance 
     After the clinical use of platinum agents, tumor cells may show resistance to 
the treatment. There are two possible reasons to explain the carboplatin resistance: 
first, insufficient amount of carboplatin reach the target DNA; second, insufficient 
formation of carboplatin-induced DNA adducts to induce cell death.  
     Carboplatin enters cells much more slowly than other classes of small-
molecule anticancer drugs. The uptake of carboplatin is affected by many factors 
including intracellular sodium level, potassium level and pH. Recently, the major 
copper influx transporter, copper transporter 1 (CTR1), was found to play an 
important role in mediating the cellular accumulation of carboplatin. It was found 
that Saccharomyces Cerevisiae with yCTR1 gene deletion was associated with a 
decrease in the accumulation of platinum chemotherapeutic drugs (Ishida et al., 
2002). In vitro, Ctr
-/-
 mouse embryonic fibroblasts treated with a clinically 
achievable concentration of carboplatin (2 μM) showed only about 35% uptake of 
carboplatin in comparison to wild-type cells. CTR1 deficiency also led to a 2 to 3 
fold increase in carboplatin resistance (Holzer et al., 2006). On the other hand, 
increased hCTR1 expression in human small-cell lung cancer cells successfully 
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enhanced the uptake of carboplatin and made cancer cells more susceptible to 
carboplatin treatment (Song et al., 2005). In addition, carboplatin resistance is 
reduced in mice with the mCTR1 alleles deleted (Howell et al., 2008). Taken 
together, many lines of research have pointed out that CTR1 functions to mediate 
carboplatin transport and plays a key role in drug resistance.  
     Carboplatin resistance may result from an increase in DNA repair or an 
increase in damage tolerance after the formation of carboplatin-induced DNA 
adducts. Ovarian and testicular cancers are hypersensitive to platinum-induced 
DNA adducts, which is likely to be attributed to a reduced repair capacity. On the 
contrary, various carboplatin-resistant cancer cells show an increased efficacy in 
DNA adducts repair pathways (Johnson et al., 1994; O’Dwyer et al., 2000). Since 
NER is the major pathway to recover carboplatin-induced intrastrand crosslinks, 
increased NER repair may result in resistance to platinum treatment. NER needs 
the XPA complex for loading downstream factors, such as XPF and ERCC1, for 
damage removal. Moreover, primary testicular cancer cells exhibited low 
constitutive NER activity due to low expression level of XPA (Koberle et al., 
1999), XPF, and ERCC1 (Welsh et al., 2004). Also, cisplatin-resistant ovarian 
cancer cells with increased NER showed a positive correlation with ERCC1 and 
XPF expression levels (Ferry et al., 2000).  Knockdown of ERCC1 in ovarian 
cancer cells showed hypersensitivity to cisplatin-induced DNA adducts and a 
significant decrease in NER efficiency (Chang et al., 2005). Furthermore, patients 
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with ovarian cancer express increased ERCC1 mRNA levels and show clinical 
resistance to platinum-based chemotherapeutic drugs (Reed, 2005). 
     Tolerance to DNA damage also results in drug resistance. Typically, 
unrepaired DNA damage triggers cellular death (Kelland, 2007). MMR functional 
loss cannot repair DNA lesions and does not respond to apoptosis signals, 
subsequently leading to carboplatin and cisplatin resistance. Furthermore, DNA 
polymerases β and η are found to bypass DNA lesions by translesion synthesis 
(Bassett et al., 2002). 
 
1.4 SELENIUM 
     Selenium was discovered in association with tellurium (named for the Earth) in 
1817 by Jöns Jakob Berzelius. It was named after the Moon or the Moon goddess 
Selene. Selenium is a non-metal element and belongs to the group VIA of the 
periodic table together with oxygen and sulfur. Because its chemistries are similar 
to sulfur, selenium is usually found in accompany with native sulfide ores. 
Besides, selenium can substitute for sulfur in compounds or amino acids. 
Selenium was first notified as a potentially toxic chemical element, using in 
glassmaking and ceramic manufacturing, where it is used to give a red color to 
glasses. In addition, selenium is also used as an important veterinary toxin.  After 
knowing that selenium functions in regulating cellular metabolism in animals, the 
element was classified as an essential trace mineral. Selenium plays important 
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roles in the maintenance of an away of biological and physiological functions; in 
particular, it is a component of some antioxidant enzymes in human.  
     Recommended daily allowance (RDA) of selenium in the US is 55 μg/day for 
the general healthy adults and 60 to 70 μg/day during pregnancy and lactation 
(Washington, DC: National Academy Press, 2000). Inorganic forms of selenium 
are generally present in the soil and can be absorbed by plants. On the other hand, 
organic forms of selenium are high in certain foods, such as Brazil nuts, seafood, 
kidney, liver, and dairy products. Selenium deficiency is not common in the US 
since Americans consume foods grown in selenium-sufficient land and are well-
nourished. Estimated selenium intake in the US exceeds RDA value. However, 
people who live on the land deficient in selenium are at risk, being unable to fully 
express selenoproteins. In Europe, the intake is as low as 30 μg/day and some 
New Zealanders consume selenium at a level less than 30 μg per day (Duffield et 
al., 1999). Besides, in selenium-deficient regions in China, people have 
insufficient selenium intake (≤10 μg/day) (Moreno-Reyes et al., 1998).   
 
1.4.1 Selenium deficiency 
     Selenium deficiency may be exacerbated when low selenium intake is in 
combination with additional stress such as chemical exposure, UV irradiation, and 
oxidative stress. Deficiency in selenium can lead to impaired immune competence, 
susceptibility toviral infection and cardiovascular diseases. Besides, body 
selenium deficiency is associated with depression and other negative mood states, 
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including anxiety, confusion, and hostility (Hawkes and Hornbostel. 1996; 
Rayman, 2000).  
     The two well-known selenium deficient diseases are Keshan disease and 
Kashin-Beck disease. Keshan disease is named after Keshan County of 
Heilongjiang province in China, where symptoms were first described in this 
selenium deficient land. It is characterized by a congestive cardiomyopathy, 
having heart failure and pulmonary edema. Congestive cardiomyopathy is often 
fatal; especially for children and women of child-bearing age (Whanger, 1989). 
The etiology of the disease is demonstrated as the increased susceptibility of heart 
muscle to Coxsackievirus B3 due to selenium deficiency (Beck et al., 1994). 
However, the mechanism of viral infection is still unknown. Kashin-Beck disease 
is a chronic osteoarthropathy, resulting from lack of both selenium and iodine 
(Moreno-Reyes et al., 1998). Kashin-Beck disease is usually found in young 
children aged 5 to 15 that are characterized by a disorder of the bones and joints. 
Although selenium deficiency is also a problem in New Zealand, it is reflected in 
low blood selenium concentration and urinary outputs. There is no adverse 
consequences for the health of New Zealanders who consume less than 30 μg 
selenium per day. Some believe that the resident New Zealanders have adapted to 
their low selenium intake (Robinson et al., 1985).  
     When young rats were fed a selenium deficient diet for 13 weeks, they showed 
a significant decrease in serum selenium level but selenium concentration in the 
brain remains (Prohaska and Ganther, 1976). This suggests that the brain receives 
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high priority for retaining this micronutrient under dietary selenium deficiency 
(Chen and Berry, 2003).  
 
1.4.2 Selenium, human health, and cancer 
     Selenium is an important trace element to counteract the toxic effect of heavy 
metals. Together with vitamin E, selenium can detoxify arsenic and mercury. 
Some of the anti-cancer property of selenium can be attributed to its toxic effect 
The link between selenium and cancer has been known for half a century base on 
both geographic and clinical studies. In 1996, the first interventional trial, the 
Nutritional Prevention of Cancer (NPC) study, was done by using the selenized 
yeast at the dose of 200 μg/day (3 to 4 folds greater than RDA). The study was 
designed to determine the selenium effects on preventing skin cancer but 
accidentally found the link between selenium and lower mortalities and 
incidences for prostate, colorectal, and lung cancer (Clark et al., 1996).  
     One of the major follow up studies, Selenium and Vitamin E Cancer 
Prevention Trial (SELECT), did not show a role for selenomethionine in prostate 
cancer suppression. It has been noted that the form of selenium in the SELECT 
trial is different from the collection of selenium compounds in selenized yeast 
used in the NPC study. Although selenomethionine accounts for 50 to 80 % of 
total selenium in selenized yeast, other selenium species such as selenocysteine, 
methylseleninic acid (MSeA) should contribute to the efficacy of selenium 
chemoprevention observed in the NPC trial (Fritz et al., 2011). However, ample 
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pre-clinical and cell studies have indicated that MSeA is far more effective than 
selenomethionine in the suppression of tumorigenesis. An examination in PC-3 
(human prostate cancer) cells xenograft in nude mice treated with MSeA suggests 
the inhibition of tumor growth without apparent genotoxicity (Li et al., 2008).  
     Also, many human studies have shown that selenium supplementation is 
effective in increasing plasma glutathione peroxidase (GPx) activity. MSeA, L-
selenomethionine, and selenite intake are associated with optimal GPx response. 
A New Zealand clinical study published in 1999 and the WHO/FAQ/IAEA group 
published in 1996 mentioned that 40 μg selenium supplementation per day, which 
is less than the US RDA, is sufficient in achieving two thirds of maximal GPx 
antioxidant activity (Duffield et al., 1999).  GPx activity is an indicator of many 
diseases or dysfunction of tissues. In addition to prevent the onset of metabolic 
syndromes, adequate GPx activity shows a decrease in the risk of cardiovascular 
disease (Hamanishi et al., 2004) and prevents early pregnancy loss (Al-Gubory et 
al., 2010).  
 
1.4.3 Selenium toxicity 
     Selenium overdose is toxic to human health and the upper limit is set at 400 
μg/day. High selenium intake may result in type 2 diabetes by the induction of 
insulin resistant. Insulin binds to cell membrane receptors and then triggers 
hydrogen peroxide as a secondary messenger (Goldstein et al., 2005). However, 
the major selenoperoxidase, GPx1, decomposeshydrogen peroxide and thus might 
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impact the normal insulin signaling (Rayman, 2012). In addition, all forms of 
selenium can be changed directly or indirectly into hydrogen selenide that 
generates selenium dioxide, superoxide anion, and hydrogen peroxide (Combs, 
2004). Those reactive oxygen species (ROS) can interact with critical 
macromolecules, such as DNA, proteins, and lipids, leading to cell damage 
response. ATM and DNA-PK kinases activity can be activated to initiate the 
signal-transduction pathways to deal with the oxidative stress and DNA damage 
response. We have recently shown that supranutritional doses of selenium can 
induce ROS and the subsequently DNA damage response to induce early 
tumorigenesis barriers (Rocourt and Cheng, 2012).  
 
1.4.4 Selenoproteins 
     Selenium can regulate metabolic pathways through selenium-containing 
proteins. Because of the similar chemistry property with sulfur, selenium can be 
incorporated into proteins by non-specific substitution of sulfur in methionine and 
cysteine or co-translationally incorporated into selenoproteins in the form of the 
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 amino acid, selenocysteine (Sec). According to the computational sequence 
analyses, there are 25 selenoproteins in the human genome and most 
selenoprotiens are directly or indirectly involved in redox regulations (Gregory et 
al., 2003). To date, twelve selenoporoteins are well-characterized as 
oxidoreductase, including glutathione peroxidases (GPx1-4, GPx6), thioredoxin 
reductases (TrxR1-3), iodothyronine deiodinases (DIO1-3), and selenophosphate 
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synthetases 2 (SPS2). The remaining selenoproteins are named in alphabetic order, 
such as selenoprotein P (SelP) (Papp et al., 2007). 
     There is a total of five GPxs (GPx1-4, GPx6) that catalyze the decomposition 
of hydrogen peroxide or lipid hydroperoxide to water and oxygen while oxidizing 
reduced glutathione. Glutathione peroxidases 1 (GPx1) is the most abundant 
selenoprotein in liver and the main antioxidant against acute oxidative stress in 
mice (Cheng et al., 1998). Many diseases are associated with GPx1 expression 
level. For example, GPx1 expression in Alzheimer’s patients is significantly 
decreased and is considered as an indicator of disease occurrence (Vural et al., 
2010). GPx1 accounts for the effect of dietary selenium in the suppression of the 
virulence of Coxsackievirus B3 that leads to Keshan disease (Beck et al., 1994). 
     Since oxidative stress has been linked to neurodegenerative diseases, 
protecting the brain from ROS damage is critical. TrxRs expression is found to be 
high in the neuronal cells (Soerensen et al., 2008). However, TrxRs expression is 
maintained in the brain of mice fed a selenium-deficient diet, indicating a pivotal 
role of TrxRs in the brain (Schomburg et al., 2003). Moreover, SelP, a selenium 
transport protein, also plays an important role in the antioxidative defense in 
neuronal tissues (Steinbrenner and Sies, 2009). SelP is found to co-localize with 
insoluble amyloid-β (Aβ) plaques and neurofibrillary tangles, which are thought 
to increase oxidative stress and promote neuronal degeneration in the Alzheimer’s 
brain (Bellinger et al., 2008). A follow-up study showed that an increased Aβ 
toxicity and apoptosis are observed in SelP knockdown neuronal N2A cells 
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(Takemoto et al., 2010). Furthermore, reduced expression of SelP is known to be 
linked to certain cancers, such as prostate cancer (Cooper et al., 2008). 
 
1.5 RESEARCH BACKGROUND  
     Ovarian is the fifth-leading cause of cancer death among women in the United 
States (Siegel et al., 2012). Since there are no validated or proven screening tests 
for detecting ovarian cancer, most patients are diagnosed at advanced-stage. 
Fortunately, carboplatin, which is a second generation of platinum-based anti-
ovarian cancer drug, was approved for clinical used in 1989. Carboplatin has 
lower toxicity than cisplatin due to a slower leaving group. It exhibits lower 
reactivity to form DNA crosslinks which disturbs cellular replication. However, 
chemotherapy resistance may develop in ovarian cancer after drug treatment.  The 
Notch pathway is one of the causes of carboplatin resistance. In clinical study, it 
is found that 22% of high-grade serous ovarian cancer samples from stage-II-IV 
have altered NOTCH signaling (TCGA Research Network, 2012). Besides, 
another study has shown that NOTCH3 was overexpressed in 66% of high-grade 
serous carcinoma and only in 33% of low-grade tumor compared with normal 
ovarian surface epithelium (Park et al., 2006). Notch 3 receptor has extracellular 
and intracellular (NICD) domains. After receiving signal outside of cell 
membrane, NICD domain translocates into nucleus, form complex with CSL and 
the mastermind-like (MAML) family, and converts CSL into a transcriptional 
activator that promotes the transcription of genes downstream in the Notch 
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pathway (Beatus and Lendahl, 1998). NICD activates a few oncogenic pathways, 
including NF-κB. However, the primary Notch3 ligand that initiates signal 
transduction in ovarian cancer remains unclear.  
     Thus, we used OVCA429 is model to study the nature of Notch in ovarian 
cancer. OVCA429 is originally from serous of late-stage human ovarian 
adenocarcinoma, which has normal level of Notch 3 and was proven to show 
cisplatin-resistance. OVCA429 with Notch 3 overexpression is more resistant to 
platinum-based anti-cancer drugs than control cells. Hence, targeting Notch 3 may 
find a potential way to improve the efficacy of DNA damaging drugs such as 
MSeA and carboplatin. 
     The inverse relationship between selenium status and cancer incidence have 
been proven by both geographical and clinical studies (Clark et al., 1999; Rayman, 
2000). MSeA is far more effective than other forms of selenium on the 
suppression of tumor in animal and cell studies (Ip et al., 2000; Drake, 2006). 
MSeA is used as a prooxidant inducing excess ROS level which results in DNA 
damage. On the other hand, carboplatin kills tumor principally by inducing DNA 
crosslinks which inhibit DNA replication and cause DNA breaks. Besides, 
carboplatin can also induce ROS which triggers cells toward apoptosis or even 
exhibits side effects, such as cardiotoxicity and ototoxicity (Cheng et al., 2008; 
Chen et al., 2010). Thus, we believe MSeA and carboplatin have overlap efficacy 
on anti-ovarian tumor. Combining two treatments may improve the efficacy of 
cancer killing.  
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     In our findings, MSeA and carboplatin have synergistic effects in Notch 3 
overexpressed cells. The co-treatment killed Notch 3 overexpressed cells down to 

























CHAPTER 2: MATERIALS AND METHODS 
 
2.1 CELLS AND CULTURE CONDITIONS 
     The OVCA429/pCEG human ovarian carcinoma expressing a GFP empty 
vector and OVCA429/NICD3 expressing the vector carrying a constitutively 
active form of the intracellular domain of Notch3 were maintained in RPMI 1640 
(Mediatech Inc, Herndon, VA) supplemented with 10% heat-inactivated fetal 
bovine serum and 100 U/ml penicillin and streptomycin at 37°C in a 5% CO2 
incubator. Both cell lines were sorted by fluorescence-activated cell sorter (FASC) 
for GFP expression that was introduced using lentivirus, and were gifted from Dr. 
Yangxin Fu’s lab at the University of Alberta, Canada. Methylseleninic acid 
(MSeA) and N-acetylcysteine (NAC) were obtained from Sigma-Aldrich (St. 
Louis, MO), and were dissolved in phosphate-buffered saline (PBS). NAC is a 
free radical scavenger that mainly abolishes hydrogen peroxide (H2O2). 
Carboplatin was purchased from Enzo Life Sciences (Farmingdale, NY), and was 
dissolved in water. KU 60019 and NU 7026 were purchased from Tocris 
(Ellisville, MO), and were dissolved in DMSO (dimethyl sulfoxide). KU 60019 is 
a selective inhibitor of ATM (Golding et al., 2009) while NU 7026 inhibits DNA-
PKcs kinase activity (Willmore et al., 2004).  
 
2.2 SULFORHODAMINE B COLORIMETRIC ASSAY 
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     Sulforhodamine B has been used to determine drug-induced cytotoxicity, 
based on the measurement of cellular protein content for large-scale drug-
screening applications. Cells were seeded at a concentration of 10,000 OVCA429 
cells per well of 96-well plate and allow for attachment overnight. At the same 
time, cells was seeded into another plate and allowed for attachment overnight 
(Day 0). Cells were incubated with RPMI 1460 medium only (negative control), 
or the medium containing MSeA (0.25-2 μM), carboplatin (1-25 μM), KU 60019 
(3 μM), NU 7026 (10 μM), and/or NAC (10 mM) for 48 hours while cells at Day 
0 was directly fixed with the following steps. Cells were fixed with 10% 
trichloroacetic acid (TCA) for 1 hour at 4 °C and the plates were washed 5 times 
with water and air dried. 0.4% sulforhodamine B in 1% acetic acid was used to 
stain living cells for 20 minutes at room temperature. After staining, unbound dye 
was removed by washing 5 times with 1% acetic acid and plates were air dried. 
Later 200 μL of 10 mM unbuffered TRIS base (pH 10.5) was added to each of the 
wells and incubated for 30 minutes at 37 °C. Finally, cellular protein content was 
measured by a plate reader (BMG LabTech, Cary, NC) at 492nm. Percentage of 
cell viability was calculated using the formula below (Vichai and Kirtikara, 2006). 
                     
                        
                             
      
 
2.3 IMMUNOFLUORESCENCE 
     Cells were seeded onto sterilized coverslips and incubated with MSeA, 
carboplatin, KU 60019 and/or NU 7026 for 24 hours. After treatment, cells were 
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first washed 3 times (5 minutes per wash) with PBS, fixed in 4% 
paraformaldehyde for 15 minutes at RT and permeabilized in 90% methanol for 
10 minutes at -20 °C. After another 3 times of washing in PBS, cells were then 
incubated in 0.3% Triton-X for 15 minutes at RT. Cells were then washed 3 times 
with PBS before being blocked in 3% BSA in PBS for 30 minutes. Next, the 
coverslips were incubated overnight at 4 °C with anti-pATM S1981 (1:300; 
Rockland, Gilbertsville, PA), anti- pDNA-PKcs S2056 (1:300, Abcam), and 
γH2AX (phospho-H2AX on Ser139, 1:500, Abcam). Coverslips were washed in 
PBS with 0.1% Tween-20 for 5 times and then were incubated with secondary 
antibodies (Alexa 594 goat anti-mouse lgG, Invitrogen) for 1 hour at RT in dark. 
After washing in PBS with 0.1% Tween-20 for 5 times, coverslips were mounted 
onto slides with a drop of ProLong®  Gold antifade reagent containing DAPI 
(Invitrogen, Grand Island, NY). All the images were taken under the same 
parameters of brightness, contrast, and exposure time by using a Zeiss Axio 
Observer Z1m fluorescence microscope (Carl Zeiss, Oberkochen, Germany). 
Photos were processed using deconvolution with the software AxioVision Release 
4.7.2.0. The pATM S1981, pDNA-PKcs S2056, and γH2AX focus-positive cells 
are defined as those containing at least five foci (Camphausen et al., 2004). 
 
2.4 FLOW CYTOMETRY ASSAY 
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     Flow cytometry assay is widely used to determine the ratio of cells in different 
phases of cell cycle by measuring the amount of DNA content in cells. Propidium 
iodide (PI) is a commonly used nuclei fluorescent dye which binds to the DNA 
double helix in the nuclei and requires blue light as the excitation source (e.g., 
488 nm argon ion laser). The different parts of the cell cycle are determined based 
on the intensity of fluorescence of the nuclei. 
     Cells were cultured in 10 cm
2
 dishes and treated with 2 μM MSeA and 5 μM 
carboplatin for 24 hours. The cell culture medium was collected before 
trypsinizing cells from dishes to completely collect G2/M cells. Then the cells 
were incubated in trypsin/EDTA for 30 min to ensure complete detachment and 
separation as single cells. Cells were collected into centrifuge tubes, resuspended 
in ice-cold PBS, and centrifuged at 4
o
C with a speed of 500×g for 5 min. Cells 
were washed again with cold PBS and resuspended by pipetting into100 μl PBS. 
Each tube was vortexing while adding 5 mL of -20
o
C 70% ethanol dropwise for 
fixation. Samples were stored at -20°C overnight. Prior to the analysis, samples 
were centrifuged at 4
o
C at a speed of 500×g for 5 min. Fixative ethanol was 
aspirated, and cells were washed with 5 mL PBS twice at 4
o
C at a speed of 500×g 
for 5 min. After supernatant was taken out, cells were vortexed and resuspended 
in 1 mL propidium iodide solution (25 μg/mL) containing RNaseA (100 μg/mL) 
for 30 min at room temperature in dark. The DNA was then analyzed by a 
FACScalibur cytometer with CELLQuest program (Becton Dickinson, San Jose, 
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CA). ModFit LT (Version 3.0, Verity Software House, Topsham, ME) was 
applied for cell cycle analysis on overlaid histograms. 
 
2.5 STATISTICAL ANALYSIS 
     The data were analyzed by using the SAS 9.0 software (SAS Institute Inc., 
Cary, NC). Two-tailed student’s t-test was applied to determine statistical 
significance between the treatments and the control. The level of statistical 
















CHAPTER 3: RESULTS 
 
3.1 SYNERGISTIC EFFECT OF MSEA AND CARBOPLATIN IN THE 
KILLING OF OVCA429/pCEG AND OVCA429/NICD3 CELLS 
     Ovarian carcinomas expressing a constitutively active form of the intracellular 
domain of Notch3 are more resistant to platinum therapeutic agents, such as 
carboplatin (Park et al., 2006; Park et al., 2010). We have previously shown that 
MSeA treatment kills HCT116 colorectal, PC-3 prostate and U-2 OS 
osteosarcoma cells in a manner depending on ROS (Wu et al., 2010; Qi et al., 
2010; Cheng et al., 2012). Because ROS could be involved in the Notch3 pathway 
(Cheng et al., 2008; Chen et al., 2010), we tested the hypothesis that MSeA can 
improve the desensitization of OVCA429 ovarian cells to carboplatin treatment 
when Notch 3 is expressed. The cells were treated with pharmacologically 
achievable concentration of MSeA (0.25-2 μM) (Saifo et al., 2010; Qi et al., 
2012), carboplatin (1-25 μM) (Elferink et al., 1987), or combinations of the two 
reagents. As determined by SRB assays, carboplatin (Figure 3.1.A) or MSeA 
(Figure 3.1.B) alone killed both OVCA429/pCEG and OVCA429/NICD3 cells in 
a dose-dependent manner, and the latter cells were more resistant than the former 
cells to the reagents (Table 3.1). Besides, OVCA429/NICD3 cells treated with 
0.5-1 μM MSeA exhibited a significant increase in cell viability. Interestingly, 
analyses of cell viability in the combinational treatment of a gradient 
concentration of carboplatin and MSeA (Table 3.1) suggested a synergistic effect 
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of these two reagents in OVCA429/NICD3 cells. While treatment of 
OVCA429/NICD3 cells with MSeA (2 µM) killed 13.9% of the cell, treatment of 
the cells with a gradient concentration of carboplatin (0-25 µM) did apparently 
sensitize the cell.  When the cells were co-treated with MSeA (2 µM) and a 
gradient concentration of carboplatin (0-25 µM), an exponential curve of 
increased sensitivity was observed as opposed to carboplatin treatment alone 
(Figure 3.1.C), suggesting a synergistic effect of MSeA and carboplatin in the 
killing of OVCA429/NICD3 cells. KU 60019 or NU 7026 co-treated with MSeA 
and carboplatin does not impact on cell viability while NAC co-treatment shows a 
significant reverse on cell viability in both cell lines (Figure 3.2 and 3.3). Of note, 
the combination of MSeA (2 µM) and carboplatin (25 µM) sensitized the 
refractory OVCA429/NICD3 cells to an extent similar to that in OVCA429/pCEG 












Table 3.1 Sensitivity of OVCA429/pCEG and OVCA429/NICD3 ovarian cells 
to MSeA and carboplatin. Cells were cultured in 96-well plates and treated with 
MSeA and/or carboplatin at the indicated concentration for 2 days.  Cell viability 
was assessed by SRB assay. The optical density in the condition without MSeA or 
carboplatin treatment was set as 100%. Values are mean ± S.E.M. (n = 3). 
#
, p < 






0 1 2 5 15 25 





0.25 100.2±10.2 90.0±5.4 89.9±7.9 93.5±13.8 75.3±7.2 66.1±11.3 
0.5 92.7±4.4 94.1±6.4 89.9±7.5 84.2±8.6 75.2±7.5 63.5±9.6 


















0 1 2 5 15 25 
0 100 108.5±7.0 106.0±6.4 97.1±5.7 93.2±9.3 91.7±7.5 
0.25 104.6±3.5 101.7±5.2 101.8±5.9 105.2±6.8 98.3±5.2 96.5±10.6 
0.5 117.8±4.8
#
































Figure 3.1 Synergistic effect of MSeA and carboplatin on OVCA429/NICD3 
cells. OVCA429/pCEG and OVCA429/NICD3 cells were treated with a gradient 
concentration of MSeA (A) or Carboplatin (B) for 2 days. *, p < 0.05, compare to 
OVCA429/pCEG cells. C, OVCA429/NICD3 cells were treated with carboplatin 
(0-25 µM) in the absence or presence of MSeA (2 µM) for 2 days. 
#
, p < 0.05, 
compared to predicted additive effect. Cell viability was assessed as described in 









Figure 3.2 Sensitivity of OVCA429/pCEG and OVCA429/NICD3 cells to 
protein kinase inhibitors or NAC under the same concentration of 
carboplatin. OVCA429/pCEG cells were treated with MSeA, carboplatin, and 
KU 60019 (A), NU 7026 (B), or NAC (C). OVCA429/NICD3 cells were treated 
with MSeA, carboplatin, and KU 60019 (D), NU 7026 (E), or NAC (F). Values 






Figure 3.3 Sensitivity of OVCA429/pCEG and OVCA429/NICD3 cells to 
protein kinase inhibitors or NAC under the same concentration of MSeA. 
OVCA429/pCEG cells were treated with MSeA, carboplatin, and KU 60019 (A), 
NU 7026 (B), or NAC (C). OVCA429/NICD3 cells were treated with MSeA, 
carboplatin, and KU 60019 (D), NU 7026 (E), or NAC (F). Values are mean ± 







3.2 CELL CYCLE ANALYSIS OF OVCA429/pCEG AND OVCA429/NICD3 
CELLS TREATED WITH MSEA AND CARBOPLATIN 
     To understand the nature of the synergistic effect, we first performed flow 
cytometric analyses to determine cell cycle distribution of the cells co-treated 
with MSeA (2 µM) and carboplatin (5 µM). Interestingly, the cell phase percent 
distributions are different between two cells under no treatment. 
OVAC429/NICD3 cells intrinsically contained a significantly higher percentage 
of cells in G2/M phase and a lower percentage in S and G1 phases compared with 
OVAC429/pCEG cells (Table 3.2), indicating a poor respond to chemotherapy 
due to a low proliferation (Itamochi et al., 2002; Kwintkiewicz et al., 2012). 
MSeA and carboplatin co-treatment shows significant effects on cell cycle 
changes. At day 2, the percent of S phase exhibits a significant decrease in control 
cells while the incidence of G1 phases exhibit a significant increase and the 
percent of G2/M phase exhibit a significant decrease in the Notch 3 overexpressed 
cells. However, even though there is a statistical significance, the biological 
significance is minimal. Of note, there was a time-dependent induction of sub-G1 
cell publication at day 1 and day 2 after the co-treatment in OVAC429/pCEG 
(2.2±0.4% and 8.9±1.0%) and in OVAC429/NICD3 (3.4±0.3% and 9.1±0.9%) 
cells. These results suggest that the co-treatment may induce DNA fragmentation 
in the cells, but this may not account for the resistance of OVAC429/NICD3 cells 




Table 3.2 Flow cytometric analyses of the percent G1, S, and G2/M 
OVCA429/pCEG and OVCA429/NICD3 cells treated with MSeA (2 μM) and 
carboplatin (5 μM) for 1 or 2 days. Values are mean ± S.E.M. (n = 3). *, p < 
0.05, compared to OVCA429/NICD3 cells. 
#
, p < 0.05, compared to Day 0. 
 Day 
 0 1 2 











G1, %    
OVCA429/pCEG 32.7±1.0* 34.7±2.7 34.0±2.7 
OVCA429/NICD3 13.4±0.6 12.7±0.8 15.7±0.3
#
 
S, %    
OVCA429/pCEG 27.1±3.1* 25.1±2.7 18.2±1.2
#
 
OVCA429/NICD3 12.3±0.6 13.9±0.7 12.4±0.8 
G2/M, %    
OVCA429/pCEG 39.6±2.5* 38.0±0.5 38.9±2.5 








3.3 EFFECT OF MSEA AND CARBOPLATIN CO-TREATMENT ON THE 
FORMATION OF pDNA-
OVCA429/pCEG and OVCA429/NICD3 CELLS 
     We next determined the nature of DNA damage response in the ovarian cancer 
cells co-treated with MSeA (2 µM) and carboplatin (5 µM) for 24 h. The 
phosphorylation of ATM on Ser-1981 and DNA-PKcs on Ser-2056 play crucial 
roles in the cellular response to DNA damage; they in turn phosphorylate their 
substrates such as H2AX. At 24 h, pDNA-PKcsS2056 level rose significantly in 
both OVCA429/pCEG and OVCA429/NICD3 cells, and the induction could be 
reversed in the presence of NU 7026 (Figure 3.4A). Co-treatment of NAC 
attenuated pDNA-PKcsS2056 expression in OVCA429/pCEG but not in 
OVCA429/NICD3 cells. On the other hand, the MSeA and carboplatin co-
treatment significantly induced the expression of pATMS1981 in 
OVCA429/pCEG but not in OVAC429/NICD3 cells (Figure 3.4B). The induction 
of pATMS1981 was inhibited in the presence of KU 60019 or NAC. The MSeA 
and carboplatin co-treatment did not induce H2AX formation, and H2AX level 
was not differ between OVCA429/pCEG and OVCA429/NICD3 cells before and 
after the co-treatment or in the presence of NU 7026, KU 60019 or NAC (Figure 
3.4C). Consistent with our observation, it has been shown previously that level of 
γH2AX is intrinsically low in OVCAR-3 human ovarian cancer cells, and 
carboplatin treatment even at a high dose (100 μM) does not induced H2AX 
formation (Qian et al., 2006; Fishel et al., 2007). 
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Figure 3.4 Immunofluorescent analyses of pDNA-PKcs S2056 (A), pATM 
S1981 (B) and H2AX (C)  in OVCA429/pCEG and OVCA429/NICD3 cells 
co-treated with MSeA (2 µM) and carboplatin (5 µM) for 24 h.  Cells were co-
treated with NU 7026 (10 μM), KU 60019 (10 μM) , or NAC (10 mM) Values are 
mean ± S.E.M. (n = 3). *, p < 0.05, compared to OVCA429/NICD3 cells. 
#
, p < 








3.4 EFFECT OF KU60019, NU7026, AND NAC ON THE SENSITIVITY OF 
OVCA429/pCEG AND OVCA429/NICD3 CELLS TO THE MSEA AND 
CARBOPLATIN CO-TREATMENT     
     Next, we determine whether DNA-PKcs, ATM and ROS are involved in the 
sensitivity of OVCA429/pCEG and OVCA429/NICD3 cells to MSeA and 
carboplatin co-treatment. The presence of KU 60019 (3 μM) or NU 7026 (10 μM ) 
decreased the cell viability in both OVCA429/pCEG and OVCA429/NICD3 cells 
co-treated with MSeA (2 µM) and carboplatin (25 µM) (Figure 3.5). Both MSeA 
and carboplatin has been shown previously to increase oxidative stress level in 
both animal and cell studies (Cheng et al., 2008; Chen et al., 2010). Thus, we co-
treated NAC with MSeA and carboplatin to determine whether ROS are involved 
in the sensitivity of ovarian cancer cells to the two agents. Here, we showed that 
NAC administration (10 mM) resulted in a significant increase of cell viability in 
both OVCA429/pCEG and OVCA429/NICD3 cells (Figure 3.5). The cell 
viability was significantly lower in OVCA429/NICD3 cells with MSeA and 









Figure 3.5 Effects of NU 7026, KU 60019 and NAC on the sensitivity of 
OVCA429/pCEG and OVCA429/NICD3 cells to MSeA (2 µM) and 
carboplatin (25 µM). Cells were for 2 days and cell viability was assessed by 
SRB assay as described in Table 1. *, p < 0.05, compared to OVCA429/pCEG 
cells. 
#













CHAPTER 4: DISCUSSION 
 
     In this study, we consider that Notch 3 overexpression provides the resistance 
of human ovarian carcinoma to MSeA and carboplatin-induced DNA damage. 
Continuing expression of Notch 3 can induce tumorigenesis and is even essential 
for the survival of human ovarian carcinoma (Rose, 2009). Based on our results, 
Notch 3 overexpressed human ovarian carcinomas cells are more resistant to 
MSeA or carboplatin treatment alone than control cells. Interestingly, synergistic 
effects were observed at dose 2 μM MSeA and 2-25 μM carboplatin in the Notch 
3 overexpressed cells, decreasing the cell viability down to a similar level with the 
control cells. Besides, the cells were treated with pharmacologically achievable 
concentration of MSeA (0.25-2 μM) (Saifo et al., 2010; Qi et al., 2012), 
carboplatin (1-25 μM) (Elferink et al., 1987), or combinations of the two reagents. 
In human patients receiving selenomethionine, a precursor of MSeA, a serum 
selenium concentration of 15 μM was obtained (Fakih et al., 2008); A 100% peak 
serum concentration of carboplatin  can be up to 39 µg/ml (105µM) (Oguri et al., 
1988). Based on our results and previous studies, all indicate that it may be 
potential to use MSeA to enhance carboplatin antitumor efficacy in Notch 3 
overexpressed human ovarian carcinoma cancer.  
      Cell cycle profiles showed a significant difference on the distribution of cell 
cycle between the control and Notch 3 overexpressed cells. In OVCA429/NICD3 
cells, low percent of S phase indicates a low proliferation and a poor respond to 
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chemotherapy (Itamochi et al., 2002; Kwintkiewicz et al., 2012), which is an 
evidence of one reason of drug resistance. Although the percent of G2/M phase is 
significantly higher in OVCCA429/NICD3 than in OVCA429/pCEG cells, cell 
cycle arrest was not observed. Defects in the G2/M arrest may allow damaged 
cells to enter mitosis and even undergo apoptosis (Tyagi et al., 2002). In summary, 
Notch 3 overexpression may indirectly change the distribution of cell cycle 
phases.  
     Both MSeA and carboplatin induce DNA damage response in order to kill 
cancer cells. The incidence of sub G1 phase showed a time-dependent increase 
with MSeA and carboplatin co-treatment in both cells. However, MSeA and 
carboplatin co-treatment does not impact on cell cycle distribution change. These 
results suggest that the co-treatment may induce DNA fragmentation in the cells, 
but this may not account for the resistance of OVAC429/NICD3 cells to the 
therapeutic treatment.  
     Selenium compounds trigger cell death by inducing ROS-induced DNA breaks 
while carboplatin kill cells by inducing DNA crosslinks, which may also lead to 
DNA breaks. Based on the functions of killing cells, they indicate an overlap of 
antitumor efficacy. ATM and DNA-PKcs are two major DNA damage response 
protein kinases, which conduct signals to downstream mediators to either repair 
damage or stop cell cycle. Based on the present results, either ATM inhibitor KU 
60019 or DNA-PKcs inhibitor NU 7026 administration significantly decreased 
the cell survival in both control and Notch 3 overexpressed cells. p53, which 
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induces cell growth when is upregulated by ATM, is one of the downstream 
factors of ATM. Thus, the protein kinase inhibitors results indicate that MSeA 
and carboplatin-induced cytotoxicity was not dependent on p53. This is consistent 
with other studies which were done with cisplatin to understand the relationship 
between p53 and OVCA429 cells. It is known that OVCA429 cells have wild-
type p53 function (Elbendary et al., 1994). One study has exhibited that cisplatin 
was relatively more effective against mutant/null p53 cell lines than against the 
wild-type cell lines (Hagopian et al., 1999). Two-fold dose of cisplatin is needed 
for killing OVCA429 cells than other mutant/null p53 cells. Besides, in order to 
significantly induce p53 expression level, up to 5-fold IC50 is required in 
OVCA429 cells (Hagopian et al., 1999). Another study also showed that cisplatin 
could not induce p53 in resistant cells (Siddik et al., 1998). Therefore, in 
OVCA429 with wild-type p53, ATM and DNA-PKcs are not the major roles to 
response to platinum-based-induced anticancer drug – cisplatin and carboplatin. 
Loss of DNA damage response proteins availabilities makes human ovarian 
carcinoma easier to be killed.  
     Although carboplatin-induced DNA damage is p53-independent, DNA-PKcs 
and ATM can still be activated with MSeA and carboplatin. DNA-PKcs was 
activated in both cell lines, showing that it may not be the reason to explain the 
difference of drug resistance of Notch 3 overexpressed cells. On the other hand, 
ATM activity was exhibited in control cells but not in Notch 3 overexpressed 
cells treated with MSeA and carboplatin co-treatment, indicating that it may be 
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the cause of drug resistance of Notch 3. However, the level of γH2AX did not 
increase with treatments, which may due to the characteristic of OVCA429 cells. 
In clinical study, it is found that there were sequence alternations in the ATM gene 
detected in 137 out of 270 Austian hereditary breast and ovarian cancer patients 
(Thorstenson et al., 2003). It is possible that OVCA429 cells have sequence 
alternations in the ATM gene though there is no any reference for OVCA429 cells 
at current stage. Thus, γH2AX inactivation may due to the ATM gene sequence 
alternations. Moreover, two findings referred that OVCAR-3 human ovarian 
cancer cells exhibited low expression level of γH2AX even after 100 μM 
carboplatin treatment (Qian et al., 2006; Fishel et al., 2007). Taken together, an 
increase of ATM activation may be the reason to explain the sensitivity to MSeA 
and carboplatin co-treatment in OVCA429/pCEG cells.  
     Antioxidants have been considered to reduce carboplatin-induced side effects, 
including ototoxicity (Okur et al., 2007; Moon et al., 2011), nephrotoxicity, and 
gastrointestinal toxicity (Wu et al., 2004). However, it is still controversial 
whether it is a good idea suggesting ovarian cancer patients to take NAC ROS 
scavenger or not. In our results, NAC concurrent significantly increased cell 
viabilities in both cell lines, exhibiting a reverse effect of NAC to MSeA and 
carboplatin treated human ovarian cancer cells. Notch 3 does not impact on NAC-
reversed cell survival. It is shown that NAC also blocks cisplatin-induced 
apoptosis in both lung and ovarian cancer cells (Wu et al., 2004). Another in vitro 
experiment has shown that NAC supports the metabolism of detached tumor cells 
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and could promote metastasis (Schafer et al., 2009). In summary, taking NAC can 
not only reduce side effects but promoting tumorigenesis. Finding a way to 
improve the efficacy of carboplatin as well as decrease the cellular toxicity of 
carboplatin is still a long way to go.  
     The drug resistance in ovarian cancer is also associated with BRCA1/2 
mutation/deletion, which causes genomic instability due to dysfunctional 
homologous recombination, and other potential related pathways (Hiss, 2012). In 
our project, we only focus on Notch 3 characteristics because Notch 3 
downstream target genes are associated with oncogenic, such as nuclear factor-
kappa B (NF-κB) and vascular growth factor receptor (VEGF). NF-κB and VEGF 
control the transcription of DNA and the development of new blood vessels for 
nutrient and oxygen supply in cancer, respectively. We believe that MSeA 
sensitizes Notch 3-activated OVCA429 ovarian cancer cells to carboplatin, and 











CHAPTER 5: CONCLUSION AND PROSPECTS 
 
     It is known that ovarian cancer with NICD3 overexpression shows resistance 
to carboplatin (Park et al., 2006; Park et al., 2010). Here we showed that NICD3 
expression can indirectly change cell fate by significantly decreasing the percent 
of S phase. Low percent S phase is a cause of low proliferation that may lead to 
drug resistance (Itamochi et al., 2002; Kwintkiewicz et al., 2012). However, 
NICD3 expression did not apparently impact on DNA fragmentation since there 
was no difference of the percent of Sub G1 between OVCA429/pCEG and 
OVCA429/NICD3 cells. Interestingly, the combinational treatment of carboplatin 
and MSeA sensitized the refractory OVCA429/NICD3 cells to an extent similar 
to that in OVCA429/pCEG cells in a synergistic manner. In clinical study, Notch 
3 was found to be overexpressed in 66% of high-grade serous ovarian cancer 
(Park et al., 2006). OVCA429 cells are also high-grade and the doses that we treat 
are both pharmacologically achievable. Thus, it is promising to improve 
carboplatin treatment of ovarian cancer by additional MSeA administration. 
     We found that NAC administration significantly increased cell viability in both 
cells. This result indicates that MSeA (Wu et al., 2010; Qi et al., 2010; Cheng et 
al., 2012) and carboplatin-induced ROS damage (Cheng et al., 2008; Chen et al., 
2010) can be reversed by NAC. Thus, cautious consideration of taking dietary 
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antioxidants should be taken for ovarian cancer patients to take lower the 
carboplatin efficacy. 
     ATM (Goodarzi et al., 2008) and DNA-PKcs (Sadofsky, 2001; Shrivastav et al., 
2008) can trigger cellular apoptosis and recruit downstream factors for DNA 
repair. We found that the presence of ATM or DNA-PKcs inhibitor significantly 
decreased cell survival in both OVCA429/pCEG and OVCA429/NICD3 cells.   
pDNA-PKcsS2056 can be induced by MSeA and carboplatin co-treatment in both 
cell lines. However, the expression of pATMS1981 was significantly induced in 
OVCA429/pCEG but not in OVAC429/NICD3 cells by MSeA and carboplatin 
co-treatment. Thus, the cause of drug resistance and high cell viability in 
OVAC429/NICD3 cells may due to pATMS1981 instead of pDNA-PKcsS2056 
expression level.      
     Our results indicate that Notch 3 could be a therapeutic target for malignant 
and advanced stages of ovarian adenocarcinoma due to the synergistic effect of 
carboplatin and MSeA and the change of cell cycle distribution. Targeting the 
Notch pathway has recently become a subject of intense research for 
chemotherapy. However, a preclinical study has demonstrated that preventing 
NICD 3 separation from the extracellular domain could be a new target-based 
therapy for tumors with Notch activity (McAuliffe et al., 2012). Future study 
should be proposed to suppress γ-secretase that leaves transmembrane proteins for 





1. NER: nucleotide-excision repair 
2. BER: base-excision repair 
3. MMR: mismatch repair 
4. DSB: double-strand-break repair 
5. ATM: ataxia telangiectasia-mutated 
6. CHK1: checkpoint kinase 1 
7. CHK2: checkpoint kinase 2 
8. BRCA1: breast cancer associated 1 
9. XP: xeroderma pigmentosum 
10. CS: Cockayne’s syndrome 
11. TTD: trichothiodystrophy 
12. TCR: transcription-coupled NER 
13. GGR: global genomic NER 
14. RPA: replication protein A 
15. ERCC1: excision repair cross-complementing-1 
16. SSB: single strand break 
17. UNG: uracil-DNA glycosylase 
18. TDG: thymine-DNA glycosylase 
19. OGG1: 8-oxoguanine glycosylase 
20. AP: apyrimidinic/apurinic 
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21. APE1: AP endonuclease 1 
22. 5’-dRp: 5’-deoxyribose-5-phosphate 
23. Pol β: DNA polymerase β 
24. PCNA: proliferating cell nuclear antigen  
25. RFC: replication factor C 
26. FEN1: flap endonuclease 1 
27. IDLs: Insertion/deletion lesions 
28. MutSα: MSH2/MSH6 
29. MutSβ: MSH2/MSH3 
30. HNPCC: hereditary non-polyposis colorectal carcinoma history 
31. HP: homologous recombination 
32. NHEJ: non-homologous end joining 
33. the catalytic subunit of DNA-PK: DNA-PKcs 
34. XLF: XRCC4-like factor 
35. PNK: polynucleotide kinase 
36. ssDNA: single-stranded DNA 
37. CtIP: C-terminal binding protein interacting protein 
38. MRN: MRE11-RAD50-NBS1 
39. dsDNA: double strand DNA 
40. BRCA2: breast cancer associated protein 2 
41. MDC1: DNA damage checkpoint 1 
42.  53BP1: tumor protein 53 binding protein 1 
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43. SMC1: structural maintenance of chromosomes 1 
44. Hes: Hairy enhance of split family 
45. NF-κB: nuclear factor-kappa B 
46. VEGF: vascular growth factor receptor 
47. mTOR: mammalian target of rapamycin 
48. Akt: protein kinase B 
49. ER: estrogen receptor 
50. AR: androgen receptor 
51. EGFR: epidermal growth factor receptor 
52. TCR: T cell receptor  
53. FDA: US Food and Drug Administration  
54. JM: Johnson Matthey Plc  
55. ICR: Institute of Cancer Research 
56. CBDCA:  bidentate dicarboxylate 
57. G: guanosine 
58. A: adenosine 
59. CTR1: copper transporter 1 
60. RDA: recommended daily allowance 
61. SELECT: Selenium and Vitamin E Cancer Prevention Trial 
62. MSeA: methylseleninic acid 
63. ROS: reactive oxygen species 
64. Sec: selenocysteine  
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65. GPx: glutathione peroxidase 
66. TrxR: thioredoxin reductase 
67. DIO: iodothyronine deiodinases 
68. SPS2: selenophosphate synthetases 2 
69. SelP: selenoprotein P 
70. Aβ: amyloid-β 
71. NAC: N-acetylcysteine 
72. PBS: phosphate-buffered saline 
73. H2O2: hydrogen peroxide 
74. TCA: trichloroacetic acid 
75. DMSO: dimethyl sulfoxide 
76. pATM S1981: ATM autophosphorylation at Ser-1981 
77. pDNA-PKcs S2056: pDNA-PKcs autophosphorylation at Ser-2056 












Abraham, R. T. (2001). "Cell cycle checkpoint signaling through the ATM and 
ATR kinases." Genes Dev 15(17): 2177-2196. 
Agarwal, M. L., et al. (1998). "A p53-dependent S-phase checkpoint helps to 
protect cells from DNA damage in response to starvation for pyrimidine 
nucleotides." Proc Natl Acad Sci U S A 95(25): 14775-14780. 
Aifantis, I., et al. (2008). "Molecular pathogenesis of T-cell leukaemia and 
lymphoma." Nat Rev Immunol 8(5): 380-390. 
Al-Gubory, K. H., et al. (2010). "The roles of cellular reactive oxygen species, 
oxidative stress and antioxidants in pregnancy outcomes." Int J Biochem 
Cell Biol 42(10): 1634-1650. 
Arany, I. and R. L. Safirstein (2003). "Cisplatin nephrotoxicity." Semin Nephrol 
23(5): 460-464. 
Artavanis-Tsakonas, S., et al. (1995). "Notch signaling." Science 268(5208): 225-
232. 
Azrak, R. G., et al. (2008). "Silencing survivin results in synergy between 
methylseleninic acid and paclitaxel against skov3 ovarian cancer cells." 
Cancer Biology & Therapy 7(12): 1901-1908. 
Barker, S., et al. (2005). "DNA-protein crosslinks: their induction, repair, and 
biological consequences." Mutat Res 589(2): 111-135. 
Bassett, E., et al. (2002). "Frameshifts and deletions during in vitro translesion 
synthesis past Pt-DNA adducts by DNA polymerases beta and eta." DNA 
Repair (Amst) 1(12): 1003-1016. 
Beatus, P. and U. Lendahl (1998). "Notch and neurogenesis." Journal of 
Neuroscience Research 54(2): 125-136. 
Beck, M. A., et al. (1994). "Increased virulence of a human enterovirus 
(coxsackievirus B3) in selenium-deficient mice." J Infect Dis 170(2): 351-
357. 
Bellavia, D., et al. (2000). "Constitutive activation of NF-kappaB and T-cell 
leukemia/lymphoma in Notch3 transgenic mice." EMBO J 19(13): 3337-
3348. 
Bellavia, D., et al. (2008). "Notch3: from subtle structural differences to 
functional diversity." Oncogene 27(38): 5092-5098. 
Bellinger, F. P., et al. (2008). "Association of selenoprotein p with Alzheimer's 
pathology in human cortex." J Alzheimers Dis 15(3): 465-472. 
Bray, S. J. (2006). "Notch signalling: a simple pathway becomes complex." Nat 
Rev Mol Cell Biol 7(9): 678-689. 
Budman, J. and G. Chu (2005). "Processing of DNA for nonhomologous end-
joining by cell-free extract." Embo Journal 24(4): 849-860. 
Cadron, I., et al. (2010). "The impact of enzastaurin (LY317615.HCl) on CA125 




Camphausen, K., et al. (2004). "Flavopiridol enhances human tumor cell 
radiosensitivity and prolongs expression of gammaH2AX foci." Mol 
Cancer Ther 3(4): 409-416. 
Cao, H. and Y. Wang (2009). "Fragmentation of isomeric intrastrand crosslink 
lesions of DNA in an ion-trap mass spectrometer." J Am Soc Mass 
Spectrom 20(4): 611-617. 
Cao, L., et al. (2006). "ATM-Chk2-p53 activation prevents tumorigenesis at an 
expense of organ homeostasis upon Brca1 deficiency." EMBO J 25(10): 
2167-2177. 
Celeste, A., et al. (2003). "H2AX haploinsufficiency modifies genomic stability 
and tumor susceptibility." Cell 114(3): 371-383. 
Chang, I. Y., et al. (2005). "Small interfering RNA-induced suppression of 
ERCC1 enhances sensitivity of human cancer cells to cisplatin." Biochem 
Biophys Res Commun 327(1): 225-233. 
Chappell, C., et al. (2002). "Involvement of human polynucleotide kinase in 
double-strand break repair by non-homologous end joining." EMBO J 
21(11): 2827-2832. 
Chen, H. H., et al. (2010). "Pravastatin attenuates carboplatin-induced 
nephrotoxicity in rodents via peroxisome proliferator-activated receptor 
alpha-regulated heme oxygenase-1." Mol Pharmacol 78(1): 36-45. 
Chen, J. and M. J. Berry (2003). "Selenium and selenoproteins in the brain and 
brain diseases." J Neurochem 86(1): 1-12. 
Cheng, C. F., et al. (2008). "Pravastatin attenuates carboplatin-induced 
cardiotoxicity via inhibition of oxidative stress associated apoptosis." 
Apoptosis 13(7): 883-894. 
Cheng, W. H. (2009). "Impact of inorganic nutrients on maintenance of genomic 
stability." Environ Mol Mutagen 50(5): 349-360. 
Cheng, W. H., et al. (1998). "Cellular glutathione peroxidase is the mediator of 
body selenium to protect against paraquat lethality in transgenic mice." J 
Nutr 128(7): 1070-1076. 
Cheng, W. H., et al. (2012). "Targeting Werner syndrome protein sensitizes U-2 
OS osteosarcoma cells to selenium-induced DNA damage response and 
necrotic death." Biochem Biophys Res Commun 420(1): 24-28. 
Christmann, M., et al. (2005). "Fen1 is induced p53 dependently and involved in 
the recovery from UV-light-induced replication inhibition." Oncogene 
24(56): 8304-8313. 
Clark, A. B., et al. (2000). "Functional interaction of proliferating cell nuclear 
antigen with MSH2-MSH6 and MSH2-MSH3 complexes." J Biol Chem 
275(47): 36498-36501. 
Clark, L. C., et al. (1996). "Effects of selenium supplementation for cancer 
prevention in patients with carcinoma of the skin. A randomized 




Cleaver, J. E., et al. (1994). "Prenatal-Diagnosis of Xeroderma-Pigmentosum and 
Cockayne-Syndrome." Prenatal Diagnosis 14(10): 921-928. 
Combs, G. F., Jr. (2004). "Status of selenium in prostate cancer prevention." Br J 
Cancer 91(2): 195-199. 
Cooper, M. L., et al. (2008). "Interaction between single nucleotide 
polymorphisms in selenoprotein P and mitochondrial superoxide 
dismutase determines prostate cancer risk." Cancer Res 68(24): 10171-
10177. 
Cortez, D. (2005). "Unwind and slow down: checkpoint activation by helicase 
and polymerase uncoupling." Genes Dev 19(9): 1007-1012. 
Costa, R. M., et al. (2003). "The eukaryotic nucleotide excision repair pathway." 
Biochimie 85(11): 1083-1099. 
Cruet-Hennequart, S., et al. (2009). "Characterization of the effects of cisplatin 
and carboplatin on cell cycle progression and DNA damage response 
activation in DNA polymerase eta-deficient human cells." Cell Cycle 
8(18): 3039-3050. 
Darwanto, A., et al. (2009). "Mechanisms of base selection by human single-
stranded selective monofunctional uracil-DNA glycosylase." J Biol Chem 
284(23): 15835-15846. 
Davoli, T. and T. de Lange (2011). "The causes and consequences of polyploidy 
in normal development and cancer." Annu Rev Cell Dev Biol 27: 585-610. 
Deans, A. J. and S. C. West (2011). "DNA interstrand crosslink repair and 
cancer." Nat Rev Cancer 11(7): 467-480. 
Demehri, S., et al. (2009). "Epidermal Notch1 loss promotes skin tumorigenesis 
by impacting the stromal microenvironment." Cancer Cell 16(1): 55-66. 
Demple, B., et al. (1991). "Cloning and expression of APE, the cDNA encoding 
the major human apurinic endonuclease: definition of a family of DNA 
repair enzymes." Proc Natl Acad Sci U S A 88(24): 11450-11454. 
Donzelli, E., et al. (2004). "Neurotoxicity of platinum compounds: comparison of 
the effects of cisplatin and oxaliplatin on the human neuroblastoma cell 
line SH-SY5Y." J Neurooncol 67(1-2): 65-73. 
Drake, E. N. (2006). "Cancer chemoprevention: selenium as a prooxidant, not an 
antioxidant." Med Hypotheses 67(2): 318-322. 
Dronkert, M. L. and R. Kanaar (2001). "Repair of DNA interstrand cross-links." 
Mutat Res 486(4): 217-247. 
Duffield, A. J., et al. (1999). "An estimation of selenium requirements for New 
Zealanders." Am J Clin Nutr 70(5): 896-903. 
Dunnick, J. K., et al. (1987). "Toxicity of 8-methoxypsoralen, 5-methoxypsoralen, 
3-carbethoxypsoralen, or 5-methylisopsoralen with ultraviolet radiation in 
the hairless (HRA/Skh) mouse." Toxicol Appl Pharmacol 89(1): 73-80. 
Eastman, A. and M. A. Barry (1987). "Interaction of trans-
diamminedichloroplatinum(II) with DNA: formation of monofunctional 




El-Bayoumy, K. (2009). "The negative results of the SELECT study do not 
necessarily discredit the selenium-cancer prevention hypothesis." Nutr 
Cancer 61(3): 285-286. 
Elbendary, A., et al. (1994). "Transforming growth factor beta 1 can induce 
CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer 
cells." Cell Growth Differ 5(12): 1301-1307. 
Evans, E., et al. (1997). "Open complex formation around a lesion during 
nucleotide excision repair provides a structure for cleavage by human 
XPG protein." EMBO J 16(3): 625-638. 
Fakih, M. G., et al. (2008). "A phase I and pharmacokinetic study of 
selenomethionine in combination with a fixed dose of irinotecan in solid 
tumors." Cancer Chemother Pharmacol 62(3): 499-508 
Falck, J., et al. (2005). "Conserved modes of recruitment of ATM, ATR and 
DNA-PKcs to sites of DNA damage." Nature 434(7033): 605-611. 
Falck, J., et al. (2001). "The ATM-Chk2-Cdc25A checkpoint pathway guards 
against radioresistant DNA synthesis." Nature 410(6830): 842-847. 
Ferry, K. V., et al. (2000). "Increased nucleotide excision repair in cisplatin-
resistant ovarian cancer cells: role of ERCC1-XPF." Biochem Pharmacol 
60(9): 1305-1313. 
Fishel, M. L., et al. (2007). "Manipulation of base excision repair to sensitize 
ovarian cancer cells to alkylating agent temozolomide." Clin Cancer Res 
13(1): 260-267. 
Forrest, R. A., et al. (2012). "Activation of DNA damage response pathways as a 
consequence of anthracycline-DNA adduct formation." Biochem 
Pharmacol 83(12): 1602-1612. 
Fortini, P. and E. Dogliotti (2007). "Base damage and single-strand break repair: 
mechanisms and functional significance of short- and long-patch repair 
subpathways." DNA Repair (Amst) 6(4): 398-409. 
Fritz, H., et al. (2011). "Selenium and lung cancer: a systematic review and meta 
analysis." PLoS One 6(11): e26259. 
Gao, R. J., et al. (2012). "Methylseleninic acid is a novel suppressor of aromatase 
expression." Journal of Endocrinology 212(2): 199-205. 
Gao, Z., et al. (2011). "C terminus of Clostridium perfringens enterotoxin 
downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and 
Carboplatin." Clin Cancer Res 17(5): 1065-1074. 
Garcia, A. and J. J. Kandel (2012). "Notch: a key regulator of tumor angiogenesis 
and metastasis." Histol Histopathol 27(2): 151-156. 
Gellon, L., et al. (2008). "Intrinsic 5 '-deoxyribose-5-phosphate lyase activity in 
Saccharomyces cerevisiae Trf4 protein with a possible role in base 
excision DNA repair." DNA Repair (Amst) 7(2): 187-198. 
Goldstein, B. J., et al. (2005). "Role of insulin-induced reactive oxygen species in 
the insulin signaling pathway." Antioxid Redox Signal 7(7-8): 1021-1031. 
Goodarzi, A. A., et al. (2008). "ATM signaling facilitates repair of DNA double-
strand breaks associated with heterochromatin." Mol Cell 31(2): 167-177. 
67 
 
Goodarzi, A. A., et al. (2008). "ATM signaling facilitates repair of DNA double-
strand breaks associated with heterochromatin." Mol Cell 31(2): 167-177. 
Gruenert, D. C., et al. (1985). "Induction of DNA-DNA cross-link formation in 
human cells by various psoralen derivatives." Cancer Res 45(11 Pt 1): 
5394-5398. 
Hagopian, G. S., et al. (1999). "Expression of p53 in cisplatin-resistant ovarian 
cancer cell lines: modulation with the novel platinum analogue (1R, 2R-
diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV)." Clin 
Cancer Res 5(3): 655-663. 
Hamanishi, T., et al. (2004). "Functional variants in the glutathione peroxidase-1 
(GPx-1) gene are associated with increased intima-media thickness of 
carotid arteries and risk of macrovascular diseases in japanese type 2 
diabetic patients." Diabetes 53(9): 2455-2460. 
Hanaoka, T., et al. (1997). "Elevated serum levels of pantropic p53 proteins in 
chromium workers." Scand J Work Environ Health 23(1): 37-40. 
Hawkes, W. C. and L. Hornbostel (1996). "Effects of dietary selenium on mood 
in healthy men living in a metabolic research unit." Biol Psychiatry 39(2): 
121-128. 
Helleday, T., et al. (2007). "DNA double-strand break repair: from mechanistic 
understanding to cancer treatment." DNA Repair (Amst) 6(7): 923-935. 
High, F. A. and J. A. Epstein (2008). "The multifaceted role of Notch in cardiac 
development and disease." Nat Rev Genet 9(1): 49-61. 
Hinz, J. M. (2010). "Role of homologous recombination in DNA interstrand 
crosslink repair." Environ Mol Mutagen 51(6): 582-603. 
Hiss, D. (2012). "OptimizingMolecular-Targeted Therapies in Ovarian Cancer: 
The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell 
Signaling Pathways." J Oncol 2012:737981. 
Hoeijmakers, J. H. (2001). "Genome maintenance mechanisms for preventing 
cancer." Nature 411(6835): 366-374. 
Holzer, A. K., et al. (2006). "Contribution of the major copper influx transporter 
CTR1 to the cellular accumulation of cisplatin, carboplatin, and 
oxaliplatin." Mol Pharmacol 70(4): 1390-1394. 
Howell, S. B. (2008). "Pharmacologic principles of intraperitoneal chemotherapy 
for the treatment of ovarian cancer." Int J Gynecol Cancer 18 Suppl 1: 20-
25. 
Ide, H., et al. (2011). "Repair and biochemical effects of DNA-protein 
crosslinks." Mutat Res 711(1-2): 113-122. 
Iijima, K., et al. (2008). "Dancing on damaged chromatin: functions of ATM and 
the RAD50/MRE11/NBS1 complex in cellular responses to DNA 
damage." J Radiat Res 49(5): 451-464. 
Ip, C., et al. (2000). "In vitro and in vivo studies of methylseleninic acid: evidence 
that a monomethylated selenium metabolite is critical for cancer 
chemoprevention." Cancer Res 60(11): 2882-2886. 
68 
 
Ishida, S., et al. (2002). "Uptake of the anticancer drug cisplatin mediated by the 
copper transporter Ctr1 in yeast and mammals." Proc Natl Acad Sci U S A 
99(22): 14298-14302. 
Itamochi, H., et al. (2002). "Low proliferation activity may be associated with 
chemoresistance in clear cell carcinoma of the ovary." Obstet Gynecol 
100(2): 281-287. 
Jacobson, G. K. (2010). "Dietary selenium and selenized yeast." Agro Food 
Industry Hi-Tech 21(4): 14-16. 
Janus, F., et al. (1999). "The dual role model for p53 in maintaining genomic 
integrity." Cell Mol Life Sci 55(1): 12-27. 
Jiricny, J. (2006). "The multifaceted mismatch-repair system." Nat Rev Mol Cell 
Biol 7(5): 335-346. 
Johnson, S. W., et al. (1994). "Relationship between platinum-DNA adduct 
formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and 
-resistant human ovarian cancer cells." Cancer Res 54(22): 5911-5916. 
Joutel, A. and E. Tournier-Lasserve (1998). "Notch signalling pathway and 
human diseases." Semin Cell Dev Biol 9(6): 619-625. 
Kanaar, R. and C. Wyman (2008). "DNA repair by the MRN complex: break it to 
make it." Cell 135(1): 14-16. 
Kao, S. C., et al. (2011). "Second-line therapy for castrate-resistant prostate 
cancer: a literature review." Asia Pac J Clin Oncol 7(3): 212-223. 
Kelland, L. (2007). "The resurgence of platinum-based cancer chemotherapy." 
Nat Rev Cancer 7(8): 573-584. 
Klinakis, A., et al. (2011). "A novel tumour-suppressor function for the Notch 
pathway in myeloid leukaemia." Nature 473(7346): 230-233. 
Koberle, B., et al. (1999). "Defective repair of cisplatin-induced DNA damage 
caused by reduced XPA protein in testicular germ cell tumours." Curr Biol 
9(5): 273-276. 
Koch, C. A., et al. (2004). "Xrcc4 physically links DNA end processing by 
polynucleotide kinase to DNA ligation by DNA ligase IV." EMBO J 
23(19): 3874-3885. 
Kojima, M., et al. (1994). "Potentiation of cis-diammine(1,1-
cyclobutanedicarboxylato)platinum(II) by amphotericin B in BALB/c 
nude mice bearing human ovarian carcinoma cells." Jpn J Cancer Res 
85(11): 1159-1164. 
Kovall, R. A. (2008). "More complicated than it looks: assembly of Notch 
pathway transcription complexes." Oncogene 27(38): 5099-5109. 
Kozekov, I. D., et al. (2003). "DNA interchain cross-links formed by acrolein and 
crotonaldehyde." J Am Chem Soc 125(1): 50-61. 
Kryukov, G. V., et al. (2003). "Characterization of mammalian selenoproteomes." 
Science 300(5624): 1439-1443. 
Kuhne, M., et al. (2004). "A double-strand break repair defect in ATM-deficient 
cells contributes to radiosensitivity." Cancer Res 64(2): 500-508. 
69 
 
Kunkel, T. A. and D. A. Erie (2005). "DNA mismatch repair." Annu Rev 
Biochem 74: 681-710. 
Kwintkiewicz, J., et al. (2012). "Metastasis-associated protein 3 (MTA3) 
regulates G2/M progression in proliferating mouse granulosa cells." Biol 
Reprod 86(3): 1-8. 
Langerak, P. and P. Russell (2011). "Regulatory networks integrating cell cycle 
control with DNA damage checkpoints and double-strand break repair." 
Philos Trans R Soc Lond B Biol Sci 366(1584): 3562-3571. 
Larson, C. A., et al. (2009). "The role of the mammalian copper transporter 1 in 
the cellular accumulation of platinum-based drugs." Mol Pharmacol 75(2): 
324-330. 
Ledermann, J. A., et al. (2010). "Inhibition of carboplatin-induced DNA 
interstrand cross-link repair by gemcitabine in patients receiving these 
drugs for platinum-resistant ovarian cancer." Clin Cancer Res 16(19): 
4899-4905. 
Lee, J. H. and T. T. Paull (2005). "ATM activation by DNA double-strand breaks 
through the Mre11-Rad50-Nbs1 complex." Science 308(5721): 551-554. 
Lee, K. B., et al. (2012). "CYR61 controls p53 and NF-kappaB expression 
through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer 
cells." Cancer Lett 315(1): 86-95. 
Lewis, L. K., et al. (2004). "Role of the nuclease activity of Saccharomyces 
cerevisiae Mre11 in repair of DNA double-strand breaks in mitotic cells." 
Genetics 166(4): 1701-1713. 
Li, G. X., et al. (2008). "Superior in vivo inhibitory efficacy of methylseleninic 
acid against human prostate cancer over selenomethionine or selenite." 
Carcinogenesis 29(5): 1005-1012. 
Li, J. and D. F. Stern (2005). "DNA damage regulates Chk2 association with 
chromatin." J Biol Chem 280(45): 37948-37956. 
Lieber, M. R., et al. (2004). "The mechanism of vertebrate nonhomologous DNA 
end joining and its role in V(D)J recombination." DNA Repair (Amst) 
3(8-9): 817-826. 
Limbo, O., et al. (2007). "Ctp1 is a cell-cycle-regulated protein that functions 
with Mre11 complex to control double-strand break repair by homologous 
recombination." Mol Cell 28(1): 134-146. 
Liu, H., et al. (2010). "Notch3 is critical for proper angiogenesis and mural cell 
investment." Circ Res 107(7): 860-870. 
Lobrich, M., et al. (2010). "gammaH2AX foci analysis for monitoring DNA 
double-strand break repair: strengths, limitations and optimization." Cell 
Cycle 9(4): 662-669. 
Lobry, C., et al. (2011). "Oncogenic and tumor suppressor functions of Notch in 
cancer: it's NOTCH what you think." J Exp Med 208(10): 1931-1935. 
Lord, C. J., et al. (2006). "Targeting the double-strand DNA break repair pathway 
as a therapeutic strategy." Clin Cancer Res 12(15): 4463-4468. 
70 
 
Lundin, C., et al. (2002). "Different roles for nonhomologous end joining and 
homologous recombination following replication arrest in mammalian 
cells." Mol Cell Biol 22(16): 5869-5878. 
Ma, Y., et al. (2005). "Repair of double-strand DNA breaks by the human 
nonhomologous DNA end joining pathway: the iterative processing 
model." Cell Cycle 4(9): 1193-1200. 
Ma, Y., et al. (2002). "Hairpin opening and overhang processing by an 
Artemis/DNA-dependent protein kinase complex in nonhomologous end 
joining and V(D)J recombination." Cell 108(6): 781-794. 
Maillard, I. and W. S. Pear (2003). "Notch and cancer: best to avoid the ups and 
downs." Cancer Cell 3(3): 203-205. 
Malina, J., et al. (2007). "Conformation of DNA GG intrastrand cross-link of 
antitumor oxaliplatin and its enantiomeric analog." Biophys J 93(11): 
3950-3962. 
Mao, Z., et al. (2008). "DNA repair by nonhomologous end joining and 
homologous recombination during cell cycle in human cells." Cell Cycle 
7(18): 2902-2906. 
Matsumoto, Y. (2001). "Molecular mechanism of PCNA-dependent base excision 
repair." Prog Nucleic Acid Res Mol Biol 68: 129-138. 
McAuliffe, S. M., et al. (2012). "Targeting Notch, a key pathway for ovarian 
cancer stem cells, sensitizes tumors to platinum therapy." Proc Natl Acad 
Sci U S A 109(43): E2939-2948. 
McCabe, K. M., et al. (2009). "DNA interstrand crosslink repair in mammalian 
cells." J Cell Physiol 220(3): 569-573. 
McHugh, P. J., et al. (2000). "Repair of intermediate structures produced at DNA 
interstrand cross-links in Saccharomyces cerevisiae." Mol Cell Biol 20(10): 
3425-3433. 
McHugh, P. J., et al. (2001). "Repair of DNA interstrand crosslinks: molecular 
mechanisms and clinical relevance." Lancet Oncol 2(8): 483-490. 
Merk, O. and G. Speit (1998). "Significance of formaldehyde-induced DNA-
protein crosslinks for mutagenesis." Environ Mol Mutagen 32(3): 260-268. 
Misdraji, J., et al. (2004). "Defective mismatch repair in the pathogenesis of low-
grade appendiceal mucinous neoplasms and adenocarcinomas." Mod 
Pathol 17(12): 1447-1454. 
Mitchell, R. J., et al. (2002). "Mismatch repair genes hMLH1 and hMSH2 and 
colorectal cancer: a HuGE review." Am J Epidemiol 156(10): 885-902. 
Moon, I. J., et al. (2011). "N-acetylcysteine and N-nitroarginine methyl ester 
attenuate Carboplatin-induced ototoxicity in dissociated spiral ganglion 
neuron cultures." Clin Exp Otorhinolaryngol 4(1): 11-17. 
Moreno-Reyes, R., et al. (1998). "Kashin-Beck osteoarthropathy in rural Tibet in 
relation to selenium and iodine status." N Engl J Med 339(16): 1112-1120. 
Mosner, J., et al. (1995). "Negative feedback regulation of wild-type p53 
biosynthesis." EMBO J 14(18): 4442-4449. 
71 
 
Muniandy, P. A., et al. (2010). "DNA interstrand crosslink repair in mammalian 
cells: step by step." Crit Rev Biochem Mol Biol 45(1): 23-49. 
Murray, J. M., et al. (2012). "DNA double-strand break repair within 
heterochromatic regions." Biochem Soc Trans 40(1): 173-178. 
Nicolas, M., et al. (2003). "Notch1 functions as a tumor suppressor in mouse 
skin." Nat Genet 33(3): 416-421. 
Noll, D. M., et al. (2006). "Formation and repair of interstrand cross-links in 
DNA." Chem Rev 106(2): 277-301. 
O'Driscoll, M. and P. A. Jeggo (2006). "The role of double-strand break repair - 
insights from human genetics." Nat Rev Genet 7(1): 45-54. 
O'Dwyer, P. J., et al. (2000). "Clinical pharmacokinetics and administration of 
established platinum drugs." Drugs 59 Suppl 4: 19-27. 
Oguri, S., et al. (1988). "Clinical pharmacokinetics of carboplatin." J Clin 
Pharmacol 28: 208-15. 
Okur, E., et al. (2007). "Effect of N-acetylcysteine on carboplatin-induced 
ototoxicity and nitric oxide levels in a rat model." Laryngoscope 117(12): 
2183-2186. 
Okuyama, R., et al. (2004). "High commitment of embryonic keratinocytes to 
terminal differentiation through a Notch1-caspase 3 regulatory 
mechanism." Dev Cell 6(4): 551-562. 
Panelos, J. and D. Massi (2009). "Emerging role of Notch signaling in epidermal 
differentiation and skin cancer." Cancer Biology & Therapy 8(21): 1986-
1993. 
Papp, L. V., et al. (2007). "From selenium to selenoproteins: synthesis, identity, 
and their role in human health." Antioxid Redox Signal 9(7): 775-806. 
Park, J. T., et al. (2010). "Notch3 overexpression is related to the recurrence of 
ovarian cancer and confers resistance to carboplatin." Am J Pathol 177(3): 
1087-1094. 
Park, J. T., et al. (2006). "Notch3 gene amplification in ovarian cancer." Cancer 
Res 66(12): 6312-6318. 
Paull, T. T., et al. (2000). "A critical role for histone H2AX in recruitment of 
repair factors to nuclear foci after DNA damage." Curr Biol 10(15): 886-
895. 
Podhorecka, M., et al. (2010). "H2AX Phosphorylation: Its Role in DNA Damage 
Response and Cancer Therapy." J Nucleic Acids 2010. 
Poklar, N., et al. (1996). "Influence of cisplatin intrastrand crosslinking on the 
conformation, thermal stability, and energetics of a 20-mer DNA duplex." 
Proc Natl Acad Sci U S A 93(15): 7606-7611. 
Prohaska, J. R. and H. E. Ganther (1976). "Selenium and glutathione peroxidase 
in developing rat brain." J Neurochem 27(6): 1379-1387. 
Purow, B. (2012). "Notch inhibition as a promising new approach to cancer 
therapy." Adv Exp Med Biol 727: 305-319. 
72 
 
Qi, Y., et al. (2010). "Selenium compounds activate ATM-dependent DNA 
damage response via the mismatch repair protein hMLH1 in colorectal 
cancer cells." J Biol Chem 285(43): 33010-33017. 
Qian, X., et al. (2006). "Activity of PXD101, a histone deacetylase inhibitor, in 
preclinical ovarian cancer studies." Mol Cancer Ther 5(8): 2086-2095. 
Rabik, C. A. and M. E. Dolan (2007). "Molecular mechanisms of resistance and 
toxicity associated with platinating agents." Cancer Treat Rev 33(1): 9-23. 
Radtke, F. and K. Raj (2003). "The role of Notch in tumorigenesis: oncogene or 
tumour suppressor?" Nat Rev Cancer 3(10): 756-767. 
Rayman, M. P. (2000). "The importance of selenium to human health." Lancet 
356(9225): 233-241. 
Rayman, M. P. (2012). "Selenium and human health." Lancet 379(9822): 1256-
1268. 
Rayman, M. P., et al. (2009). "Selenium and vitamin E supplementation for 
cancer prevention." JAMA 301(18): 1876; author reply 1877. 
Reed, E. (2005). "ERCC1 and clinical resistance to platinum-based therapy." Clin 
Cancer Res 11(17): 6100-6102. 
Reich, N. C. and A. J. Levine (1984). "Growth regulation of a cellular tumour 
antigen, p53, in nontransformed cells." Nature 308(5955): 199-201. 
Rizvi, I., et al. (2010). "Synergistic enhancement of carboplatin efficacy with 
photodynamic therapy in a three-dimensional model for micrometastatic 
ovarian cancer." Cancer Res 70(22): 9319-9328. 
Rizzo, P., et al. (2008). "Rational targeting of Notch signaling in cancer." 
Oncogene 27(38): 5124-5131. 
Robinson, J. R., et al. (1985). "Urinary excretion of selenium by New Zealand 
and North American human subjects on differing intakes." Am J Clin Nutr 
41(5): 1023-1031. 
Rocourt, C. R., et al. (2012). "The catalytic subunit of DNA-dependent protein 
kinase is downstream of ATM and feeds forward oxidative stress in the 
selenium-induced senescence response." J Nutr Biochem. 
Rogakou, E. P., et al. (1999). "Megabase chromatin domains involved in DNA 
double-strand breaks in vivo." J Cell Biol 146(5): 905-916. 
Rose, S. L. (2009). "Notch signaling pathway in ovarian cancer." Int J Gynecol 
Cancer 19(4): 564-566. 
Rosenberg, B., et al. (1965). "Inhibition of Cell Division in Escherichia Coli by 
Electrolysis Products from a Platinum Electrode." Nature 205: 698-699. 
Rosenberg, B., et al. (1969). "Platinum compounds: a new class of potent 
antitumour agents." Nature 222(5191): 385-386. 
Rothkamm, K., et al. (2003). "Pathways of DNA double-strand break repair 
during the mammalian cell cycle." Mol Cell Biol 23(16): 5706-5715. 
Ruppenthal, S. L., et al. (2007). "Interference between p53 and cdc25C in cell 
cycle regulation." Int J Oncol 31(2): 345-352. 
Sadofsky, M. J. (2001). "The RAG proteins in V(D)J recombination: more than 
just a nuclease." Nucleic Acids Res 29(7): 1399-1409. 
73 
 
Schafer, Z. T., et al. (2009). "Antioxidant and oncogene rescue of metabolic 
defects caused by loss of matrix attachment." Nature 461(7260): 109-113. 
Schomburg, L., et al. (2003). "Gene disruption discloses role of selenoprotein P in 
selenium delivery to target tissues." Biochem J 370(Pt 2): 397-402. 
Schrauzer, G. N. (2000). "Selenomethionine: a review of its nutritional 
significance, metabolism and toxicity." J Nutr 130(7): 1653-1656. 
Shaham, J., et al. (2003). "DNA-protein crosslinks and p53 protein expression in 
relation to occupational exposure to formaldehyde." Occup Environ Med 
60(6): 403-409. 
Shih Ie, M. and B. Davidson (2009). "Pathogenesis of ovarian cancer: clues from 
selected overexpressed genes." Future Oncol 5(10): 1641-1657. 
Shrivastav, M., et al. (2008). "Regulation of DNA double-strand break repair 
pathway choice." Cell Res 18(1): 134-147. 
Siddik, Z. H., et al. (1998). "Independent pathways of p53 induction by cisplatin 
and X-rays in a cisplatin-resistant ovarian tumor cell line." Cancer Res 
58(4): 698-703. 
Siegel, R., et al. (2012). "Cancer Statistics, 2012." Ca-a Cancer Journal for 
Clinicians 62(1): 10-29. 
Soerensen, J., et al. (2008). "The role of thioredoxin reductases in brain 
development." PLoS One 3(3): e1813. 
Song, I. S., et al. (2005). "Role of human copper transporter Ctr1 in the transport 
of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-
resistant cells. (vol 4, pg 113, 2005)." Mol Cancer Ther 4(5): 864-864. 
Steinbrenner, H. and H. Sies (2009). "Protection against reactive oxygen species 
by selenoproteins." Biochim Biophys Acta 1790(11): 1478-1485. 
Stone, M. P., et al. (2008). "Interstrand DNA cross-links induced by alpha,beta-
unsaturated aldehydes derived from lipid peroxidation and environmental 
sources." Acc Chem Res 41(7): 793-804. 
Suchankova, T., et al. (2012). "Platinum-DNA interstrand crosslinks: molecular 
determinants of bending and unwinding of the double helix." J Inorg 
Biochem 108: 69-79. 
Takahashi, P., et al. (2011). "Elevated transcription of the p53 gene in early S-
phase leads to a rapid DNA-damage response during S-phase of the cell 
cycle." Apoptosis 16(9): 950-958. 
Takashima, Y., et al. (2009). "Dependence of DNA double strand break repair 
pathways on cell cycle phase in human lymphoblastoid cells." Environ 
Mol Mutagen 50(9): 815-822. 
Takemoto, A. S., et al. (2010). "Role of selenoprotein P in Alzheimer's disease." 
Ethn Dis 20(1 Suppl 1): S1-92-95. 
Thorstenson, Y. R., et al. (2003). "Contributions of ATM mutations to familial 
breast and ovarian cancer." Cancer Res 63(12): 3325-3333. 
Tien, A. C., et al. (2009). "A Notch updated." J Cell Biol 184(5): 621-629. 
74 
 
Tyagi, A. K., et al. (2002). "Silibinin strongly synergizes human prostate cancer 
DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and 
apoptosis." Clin Cancer Res 8(11):3512-9. 
Unger, F. T., et al. (2009). "DNA damage induced by cis- and carboplatin as 
indicator for in vitro sensitivity of ovarian carcinoma cells." BMC Cancer 
9: 359. 
Uto, K., et al. (2004). "Chk1, but not Chk2, inhibits Cdc25 phosphatases by a 
novel common mechanism." EMBO J 23(16): 3386-3396. 
van der Vijgh, W. J. (1991). "Clinical pharmacokinetics of carboplatin." Clin 
Pharmacokinet 21(4): 242-261. 
Vichai, V. and K. Kirtikara (2006). "Sulforhodamine B colorimetric assay for 
cytotoxicity screening." Nat Protoc 1(3): 1112-1116. 
Vural, H., et al. (2010). "Alterations of plasma magnesium, copper, zinc, iron and 
selenium concentrations and some related erythrocyte antioxidant enzyme 
activities in patients with Alzheimer's disease." J Trace Elem Med Biol 
24(3): 169-173. 
Wagstaff, A. J., et al. (1989). "Carboplatin. A preliminary review of its 
pharmacodynamic and pharmacokinetic properties and therapeutic 
efficacy in the treatment of cancer." Drugs 37(2): 162-190. 
Wang, L., et al. (2009). "Methyl-selenium compounds inhibit prostate 
carcinogenesis in the transgenic adenocarcinoma of mouse prostate model 
with survival benefit." Cancer Prev Res (Phila) 2(5): 484-495. 
Wang, T., et al. (2008). "An overview of Notch3 function in vascular smooth 
muscle cells." Prog Biophys Mol Biol 96(1-3): 499-509. 
Wang, Z., et al. (2010). "Targeting Notch signaling pathway to overcome drug 
resistance for cancer therapy." Biochim Biophys Acta 1806(2): 258-267. 
Wang, Z., et al. (2008). "Exploitation of the Notch signaling pathway as a novel 
target for cancer therapy." Anticancer Res 28(6A): 3621-3630. 
Wei, W. and E. W. Englander (2008). "DNA polymerase beta-catalyzed-PCNA 
independent long patch base excision repair synthesis: a mechanism for 
repair of oxidatively damaged DNA ends in post-mitotic brain." J 
Neurochem 107(3): 734-744. 
Welsh, C., et al. (2004). "Reduced levels of XPA, ERCC1 and XPF DNA repair 
proteins in testis tumor cell lines." International Journal of Cancer 110(3): 
352-361. 
Whanger, P. D. (1989). "China, a country with both selenium deficiency and 
toxicity: some thoughts and impressions." J Nutr 119(9): 1236-1239. 
Wheate, N. J., et al. (2010). "The status of platinum anticancer drugs in the clinic 
and in clinical trials." Dalton Trans 39(35): 8113-8127. 
Williams, G. J., et al. (2010). "Mre11-Rad50-Nbs1 conformations and the control 
of sensing, signaling, and effector responses at DNA double-strand 
breaks." DNA Repair (Amst) 9(12): 1299-1306. 
Wu, L., et al. (2004). "Oxidative stress is a mediator of glucose toxicity in insulin-
secreting pancreatic islet cell lines." J Biol Chem 279(13): 12126-12134. 
75 
 
Wu, M., et al. (2010). "Selenium compounds activate early barriers of 
tumorigenesis." J Biol Chem 285(16): 12055-12062. 
Xia, Y., et al. (2005). "Effectiveness of selenium supplements in a low-selenium 
area of China." Am J Clin Nutr 81(4): 829-834. 
Yao, X., et al. (2007). "Cisplatin nephrotoxicity: a review." Am J Med Sci 334(2): 
115-124. 
Zeng, Y. and Y. Wang (2006). "Sequence-dependent formation of intrastrand 
crosslink products from the UVB irradiation of duplex DNA containing a 
5-bromo-2'-deoxyuridine or 5-bromo-2'-deoxycytidine." Nucleic Acids 
Res 34(22): 6521-6529. 
Zhou, B. B. and J. Bartek (2004). "Targeting the checkpoint kinases: 
chemosensitization versus chemoprotection." Nat Rev Cancer 4(3): 216-
225. 
Zou, X., et al. (2001). "The cell cycle-regulatory CDC25A phosphatase inhibits 
apoptosis signal-regulating kinase 1." Mol Cell Biol 21(14): 4818-4828. 
 
 
 
 
 
 
 
 
 
 
 
 
 
